0001558370-20-010449.txt : 20200812 0001558370-20-010449.hdr.sgml : 20200812 20200812172706 ACCESSION NUMBER: 0001558370-20-010449 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200812 DATE AS OF CHANGE: 20200812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hepion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001583771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462783806 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36856 FILM NUMBER: 201096302 BUSINESS ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 BUSINESS PHONE: 732-902-4000 MAIL ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 FORMER COMPANY: FORMER CONFORMED NAME: ContraVir Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130806 10-Q 1 hepa-20200630x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2020

Or

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number 001-36856

HEPION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)



Delaware (State or other jurisdiction of incorporation or organization)		46-2783806 (I.R.S. Employer Identification Number)

399 Thornall Street, First Floor Edison, New Jersey 08837 (Address of Principal Executive Offices)

(732) 902-4000

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	HEPA	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.:


Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☒	Smaller reporting company ☒	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s Common Stock outstanding as of August 5, 2020 was 9,025,153.

Table of Contents

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q for Hepion Pharmaceuticals, Inc. may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Item 1A. Risk Factors and elsewhere in the audited condensed consolidated financial statements as of and for the year ended December 31, 2019 contained in the Company’s Annual Report on Form 10-K and 10-K/A filed with the Securities and Exchange Commission. These factors include the uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate safety and efficacy in larger-scale clinical trials, the risk that we will not obtain approval to market our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change and thus you should not unduly rely on these statements. Cautionary Note Regarding Forward-Looking Statements.

Table of Contents

HEPION PHARMACEUTICALS, INC.

FORM 10-Q

TABLE OF CONTENTS


		Page
PART I—FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (unaudited):	3
	Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019	3
	Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2020 and 2019	4
	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2020 and 2019	5
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019	7
	Notes to Condensed Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	31

PART II—OTHER INFORMATION

Item 1A.	Risk Factors	32
Item 6.	Exhibits	32
SIGNATURES		33

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)



	June 30,		December 31,
	2020		2019
Assets
Current assets:
Cash	$	17,561,813	$	13,922,972
Prepaid expenses		607,126		465,693
Total current assets		18,168,939		14,388,665
Property and equipment, net		52,679		57,166
Right-of-use assets		672,801		797,913
In-process research and development		3,190,000		3,190,000
Goodwill		1,870,924		1,870,924
Other assets		128,289		127,939
Total assets	$	24,083,632	$	20,432,607

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	972,362	$	491,557
Accrued expenses		1,356,170		493,636
Operating lease liabilities, current		274,604		266,696
Total current liabilities		2,603,136		1,251,889
Contingent consideration		2,510,000		2,430,000
Long-term debt		176,585		—
Deferred tax liability		49,177		18,752
Operating lease liabilities, non-current		418,258		540,751
Derivative financial instruments, at estimated fair value—warrants		34,398		5,623
Total liabilities		5,791,554		4,247,015
Commitments and contingencies (Note 11)
Stockholders’ equity:
Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively.		855,808		855,808
Series C convertible preferred stock, stated value $1,000 per share, 1,827 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively.		861,033		861,033
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 9,025,061 and 3,760,255 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively.		901		375
Additional paid in capital		108,923,663		97,651,006
Accumulated deficit		(92,349,327)		(83,182,630)
Total stockholders’ equity		18,292,078		16,185,592
Total liabilities and stockholders’ equity	$	24,083,632	$	20,432,607

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Revenues	$	—	$	—	$	—	$	—
Costs and expenses:
Research and development		2,950,340		755,659		5,587,671		1,273,699
General and administrative		1,825,074		939,909		3,374,680		2,343,570
Total operating expenses		4,775,414		1,695,568		8,962,351		3,617,269
Loss from operations		(4,775,414)		(1,695,568)		(8,962,351)		(3,617,269)

Other income (expense):
Change in fair value of debt		—		(94,154)		—		(153,795)
Interest on debt		—		(441,801)		—		(540,088)
Change in fair value of derivative instruments—warrants and contingent consideration		(69,095)		249,611		(108,775)		345,528
Loss before income taxes		(4,844,509)		(1,981,912)		(9,071,126)		(3,965,624)
Income tax (expense) benefit		(95,571)		961,014		(95,571)		961,014
Net loss		(4,940,080)		(1,020,898)		(9,166,697)		(3,004,610)
Deemed dividend (see Note 5)		—		(5,412,045)		—		(5,436,366)
Net loss attributable to common shareholders	$	(4,940,080)	$	(6,432,943)	$	(9,166,697)	$	(8,440,976)

Weighted average common shares outstanding:
Basic and diluted		8,494,518		859,827		6,420,109		556,662

Net loss per common share: (see Note 10)
Basic and diluted	$	(0.58)	$	(7.48)	$	(1.43)	$	(15.16)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)




	Preferred Stock			Preferred Stock						Additional				Total
	Series A			Series C			Common Stock			Paid in		Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Equity
Balance at December 31, 2019	85,581	$	855,808	1,827	$	861,033	3,760,255	$	375	$	97,651,006	$	(83,182,630)	$	16,185,592
Net loss	—		—	—		—	—		—		—		(4,226,617)		(4,226,617)
Stock-based compensation expense	—		—	—		—	—		—		8,246		—		8,246
Issuance of common stock, net	—		—	—		—	2,311,867		231		6,788,234		—		6,788,465
Warrant exercises	—		—	—		—	2,000		—		12,000		—		12,000
Balance at March 31, 2020	85,581		855,808	1,827		861,033	6,074,122		606		104,459,486		(87,409,247)		18,767,686
Net loss	—		—	—		—	—		—		—		(4,940,080)		(4,940,080)
Stock-based compensation expense	—		—	—		—	—		—		4,123		—		4,123
Issuance of common stock, net	—		—	—		—	2,950,939		295		4,460,054		—		4,460,349
Balance at June 30, 2020	85,581	$	855,808	1,827	$	861,033	9,025,061	$	901	$	108,923,663	$	(92,349,327)	$	18,292,078

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)



	Preferred Stock			Preferred Stock			Preferred Stock			Preferred Stock						Additional				Total
	Series A			Series C			Series D			Series E			Common Stock			Paid in		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Equity
Balance at December 31, 2018	85,581	$	855,808	1,974	$	930,311	—	$	—	—	$	—	247,013	$	25	$	76,652,839	$	(76,463,932)	$	1,975,051
Net loss	—		—	—		—	—		—	—		—	—		—		—		(1,983,711)		(1,983,711)
Stock-based compensation expense	—		—	—		—	—		—	—		—	—		—		17,506		—		17,506
Conversion of preferred stock to common	—		—	(46)		(46,000)	—		—	—		—	424		—		46,000		—		—
Accretion of discount	—		—	—		24,321	—		—	—		—	—		—		(24,321)		—		—
Issuance of common stock, private placement	—		—	—		—	—		—	—		—	47,429		5		486,278		—		486,283
Issuance of common stock, debt redemption	—		—	—		—	—		—	—		—	11,882		1		149,917		—		149,918
Balance at March 31, 2019	85,581		855,808	1,928		908,632	—		—	—		—	306,748		31		77,328,219		(78,447,643)		645,047
Net loss	—		—	—		—	—		—	—		—	—		—		—		(1,020,899)		(1,020,899)
Stock-based compensation expense	—		—	—		—	—		—	—		—	—		—		17,133		—		17,133
Issuance of preferred stock	—		—	—		—	521		312,600	10,570		6,976,201	—		—		3,802,201		—		11,091,002
Conversion of preferred stock to common	—		—	(85)		(85,000)	(521)		(521,000)	(10,570)		(10,570,002)	1,824,473		182		11,175,820		—		—
Offering costs	—		—	—		—	—		(29,526)	—		(472,311)	—		—		(536,787)		—		(1,038,624)
Placement agent warrants	—		—	—		—	—		(48,250)	—		(244,895)	—		—		293,145		—		—
Beneficial conversion feature	—		—	—		—	—		(186,692)	—		(581,350)	—		—		768,042		—		—
Accretion of beneficial conversion feature	—		—	—		—	—		186,692	—		581,350	—		—		(768,042)		—		—
Accretion of discount	—		—	—		44,941	—		286,176	—		4,311,007	—		—		(4,642,124)		—		—
Issuance of common stock, net	—		—	—		—	—		—	—		—	1,031,071		103		5,844,421		—		5,844,524
Issuance of common stock, private placement	—		—	—		—	—		—	—		—	—		—		330		—		330
Issuance of common stock, debt redemption	—		—	—		—	—		—	—		—	42,439		4		400,059		—		400,063
Warrant exercises	—		—	—		—	—		—	—		—	248,877		25		2,090,542		—		2,090,567
Balance at June 30, 2019	85,581	$	855,808	1,843	$	868,573	—	$	—	—	$	—	3,453,608	$	345	$	95,772,959	$	(79,468,542)	$	18,029,143

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)



	Six Months Ended
	June 30,
	2020		2019
Cash flows from operating activities:
Net loss	$	(9,166,697)	$	(3,004,610)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		402,857		34,637
Depreciation and amortization		13,729		12,928
Change in fair value of derivative intstrument-warrants		28,775		(395,528)
Change in fair value of contingent consideration		80,000		50,000
Change in fair value of debt		—		153,795
Non-cash interest expense		—		49,729
Amortization of debt discount recorded as interest expense		—		486,612
Change in deferred tax liability		30,425		—
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		952,851		(592,104)
Prepaid expenses and other assets		(131,256)		(117,422)
Net cash used in operating activities		(7,789,316)		(3,321,963)

Cash flows from investing activities:
Purchase of property and equipment		(11,436)		(45,334)
Proceeds from disposal of property and equipment		2,194		—
Net cash used in investing activities		(9,242)		(45,334)

Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs		11,248,814		5,844,530
Proceeds from the issuance of Series D and warrants, net of issuance costs		—		403,120
Proceeds from the issuance of Series E and warrants, net of issuance costs		—		9,649,258
Proceeds from the exercise of warrants		12,000		2,090,567
Proceeds from debt financing		176,585		1,250,000
Repayment of debt financing		—		(1,250,000)
Repayment of convertible debt		—		(303,547)
Net cash provided by financing activities		11,437,399		17,683,928
Net increase in cash		3,638,841		14,316,631
Cash at beginning of period		13,922,972		2,832,429
Cash at end of period	$	17,561,813	$	17,149,060

Supplementary disclosure of cash flow information:
Cash paid for interest	$	—	$	8,953
Supplementary disclosure of non-cash financing activities:
Conversion of Series C convertible preferred stock (part of Series C deemed dividend)	$	—	$	131,000
Conversion of Series D convertible preferred stock		—		521,000
Conversion of Series E convertible preferred stock		—		10,570,002
Accretion of Series C preferred stock discount upon conversion		—		4,666,445
Beneficial conversion factor of preferred stock accreted as deemed dividend		—		768,042
Issuance of common stock for debt redemption		—		500,428
Adoption of lease accounting		—		692,918
Warrants issued to placement agent		—		293,145

The accompanying notes are an integral part of these condensed consolidated financial statements.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Business Overview

Hepion Pharmaceuticals, Inc. (we, our, or us) is a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease.

On July 18, 2019, we filed a certificate of amendment (the “Certificate of Amendment”) to our certificate of incorporation (the “Certificate”) to change our name from “ContraVir Pharmaceuticals, Inc.” to “Hepion Pharmaceuticals, Inc.” The name change became effective as of July 18, 2019.

We are developing CRV431 as our lead molecule. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. To date, in vitro and/or in vivo studies have demonstrated reductions in HBV DNA, HBsAg, HBeAg, inhibition of virus uptake (NTCP transport inhibition), and stimulation of innate immunity. Importantly, in vivo studies in a NASH model of fibrosis and HCC have repeatedly demonstrated CRV431 reduces fibrosis scores and overall liver tumor burden. Hence, CRV431 is a pleiotropic molecule that may not only treat liver disease but may also serve to reduce important risk factors (e.g., HBV) for developing the disease. We have completed a phase 1 study with CRV431 demonstrating safety, tolerability, and pharmacokinetics (PK).

CRV431

On May 10, 2018, we submitted an Investigational New Drug Application (“IND”) to the U.S. Food and Drug Administration (“FDA”) to support initiation of our CRV431 HBV clinical development program in the United States and received approval in June 2018. We completed the first segment of Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (“Ciclofilin”) and we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June 2016, to the Ciclofilin shareholders.

On June 17, 2019, we submitted an IND to the FDA to support initiation of our CRV431 NASH clinical development program in the United States and received approval in July 2019.

2. Basis of Presentation and Going Concern

These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2019 was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 contained in our Annual Report on Form 10-K.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Principles of Consolidation

The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation.

Going Concern

As of June 30, 2020, we had $17.6 million in cash, we had an accumulated deficit of $92.3 million, and we had working capital of $15.6 million. For the six months ended June 30, 2020 cash used in operating activities was $7.8 million and for the three and six months ended June 30, 2020 we had a net loss of $4.9 million and $9.2 million, respectively. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through issuances of convertible debt, common stock and preferred stock. We expect to continue to incur losses for the next several years as we expand our research, development and clinical trials of CRV431. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. These condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.

COVID-19 Pandemic

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation and its impact on our financial condition, liquidity, operations, suppliers, industry, and workforce.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

to healthcare facilities and physicians' offices unless due to a health emergency. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial, related to the COVID-19 pandemic, or in obtaining sufficient supplies of clinical trial materials. Any delays in completing our clinical trials will increase our costs, slow down our product development, timeliness and approval process and delay our ability to generate revenue.

The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change and we do not yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. Although we cannot estimate the length or gravity of the impact of the COVID-19 outbreak nor estimate the potential impact to our fiscal year 2020 financial statements at this time, if the pandemic continues, it could have a material adverse effect on our results of future operations, financial position, liquidity, and capital resources, and those of the third parties on which we rely in fiscal year 2020.

On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), as amended on June 5, 2020 by the Paycheck Protection Program (“PPP”). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. On April 13, 2020, we were granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggregate amount of $176,585, pursuant to the PPP under Division A, Title I of the CARES Act. We are continuing to evaluate and examine the impacts the CARES Act may have on our business, results of operations, financial condition or liquidity.

The Loan, which was in the form of a Note dated April 13, 2020 issued by us, matures on April 13, 2022 and bears interest at a rate of 0.98% per annum, payable monthly commencing on November 13, 2020. The Note may be prepaid by us at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, rent and utilities. We intend to use the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. We have a good-faith belief that we properly satisfied all eligibility requirements for the PPP loan and we intend to comply with the loan forgiveness provisions in the legislation; however, there can be no assurance that we will obtain full forgiveness of the loan based on the legislation. The PPP Loan is reflected in the condensed consolidated balance sheet as long-term debt based upon the terms and conditions of the Loan agreement.

3. Summary of Significant Accounting Policies

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.

Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in our Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies.

Cash

As of June 30, 2020 and December 31, 2019, cash was $17.6 million and $13.9 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced losses related to these balances.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Fair Value of Financial Instruments

Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.

ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:

●	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.

●	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

●	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Financial instruments consist of cash and accounts payable, long-term debt, derivative instruments — warrants and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature, except for derivative instruments — warrants and contingent consideration, which were marked to market at the end of each reporting period. See Note 5 for additional information of the fair value of the derivative liabilities. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. See Note 6 for additional information on the fair value of the contingent consideration.

Derivative Financial Instruments

We have issued common stock warrants in connection with the execution of certain equity financings. The fair value of the warrants, which were deemed to be derivative instruments based on certain contingent put features, was recorded as a derivative liability under the provisions of ASC Topic 815 Derivatives and Hedging (“ASC 815”) upon issuance. Subsequently, the liability is adjusted to fair value as of the end of each reporting period and the changes in the fair value of derivative liabilities are recorded in the statements of operations under the caption “Change in fair value of derivative financial instruments—warrants.” See Note 5 for additional information.

The fair value of the warrants, issued in connection with the October 2015, April 2016, and April 2017 common stock offerings were deemed to be derivative instruments due to certain contingent put features, was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.

The fair value of warrants was affected by changes in inputs to the Black-Scholes option pricing model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. This model uses Level 3 inputs, including stock price volatility, in the fair value hierarchy established by ASC 820 Fair Value Measurement. At June 30, 2020 and December 31, 2019, the fair value of all warrants was $34,398 and $5,623, respectively, which are classified as a long-term derivative liability on our condensed consolidated balance sheets.

Property, equipment and depreciation

As of June 30, 2020 and December 31, 2019, we had $52,679 and $57,166, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the three months ended June 30, 2020 and 2019 was $7,202 and $8,287 respectively, and was $13,729 and $12,928 for the six months ended June 30, 2020 and 2019, respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at June 30, 2020 or December 31, 2019.

Goodwill and In-Process Research & Development

In accordance with ASC Topic 350, Intangibles — Goodwill and Other (“ASC Topic 350”), goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually, in our fourth quarter, and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired.

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable.

The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. We adopted ASU 2017-04 on January 1, 2020, and the adoption of this standard did not have a material effect on our condensed condolidated financial statements.

Goodwill relates to amounts that arose in connection with the acquisition of Ciclofilin. Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. As a result of the COVID-19 pandemic, we performed a qualitative assessment of goodwill and determined that it was not more likely than not that the fair value of our reporting was less than its carrying value. There was no impairment of goodwill for the six months ended June 30, 2020 and 2019.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

IPR&D acquired in a business combination is capitalized as indefinite-lived assets on our condensed consolidated balance sheets at the acquisition-date fair value. Once the project is completed, the carrying value of the IPR&D is reclassified to other intangible assets, net and is amortized over the estimated useful life of the asset. Post-acquisition research and development expenses related to the IPR&D projects are expensed as incurred. The projected discounted cash flow models used to estimate the fair values of our IPR&D assets, acquired in connection with the Ciclofilin acquisition, reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including: (i) probability of successfully completing clinical trials and obtaining regulatory approval; (ii) market size, market growth projections, and market share; (iii) estimates regarding the timing of and the expected costs to advance clinical programs to commercialization; (iv) estimates of future cash flows from potential product sales; and (v) a discount rate. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The use of different inputs and assumptions could increase or decrease our estimated discounted future cash flows, the resulting estimated fair values and the amounts of related impairments, if any.

If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.

As a result of the COVID-19 pandemic, we performed a qualitative assessment of IPR&D and determined that it was not more likely than not that the asset was impaired. There was no impairment of IPR&D for the six months ended June 30, 2020 and 2019.

Income Taxes

We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.

In April 2019, we transferred state net operating loss tax credits and received approximately $1.0 million in connection with the sale of the state net operating losses to a third party recorded as an income tax benefit in the consolidated statement of operations. We received approval for the sale of net operating losses through participation in the New Jersey Technology Business Tax Certificate Transfer (NOL) Program. We continue to maintain a full valuation allowance for our domestic operations. The current period income tax expense is related to our foreign operations.

Contingencies

In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Research and Development

Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, Research and Development, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.

We do not currently have any commercial biopharmaceutical products and do not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.

Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. At June 30, 2020 and December 31, 2019, we had prepaid research and development costs of $0.4 million and $0.4 million, respectively.

Share-based payments

ASC Topic 718 “Compensation—Stock Compensation” (“ASC 718”) requires companies to measure the cost of employee and non-employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. Generally, we issue stock options with only service-based vesting conditions and record the expense for awards using the straight-line method.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The estimated expected stock volatility is based on the historical volatility of our own traded stock price. The expected term of stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future.

Foreign Exchange

The functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Our reporting currency is the U.S. dollar. The assets and liabilities of Ciclofilin are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was immaterial at June 30, 2020 and December 31, 2019.

Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in other foreign exchange (gain) loss within the consolidated statements of operations. The impact of foreign exchange gains (losses) was immaterial at June 30, 2020 and December 31, 2019.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.

Net loss per share

Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.

4. Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance will be effective for us in the first quarter of 2021 on a prospective basis, and early adoption is permitted. We are currently evaluating the impact of the new guidance on our condensed consolidated financial statements.

In August of 2018, the FASB issued ASU 2018-13 — Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends disclosure requirements on fair value measurements in Topic 820. This amendment modifies the valuation process of fair value measurements by removing the disclosure requirements for the valuation processes for Level 3 fair value measurements, clarifying the timing of the measurement uncertainty disclosure, and including the changes in unrealized gains and losses for recurring Level 3 fair value measurements in other comprehensive income if held at the end of the reporting period. It also allows the disclosure of other quantitative information in lieu of the weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and should be applied prospectively for the most recent period presented in the initial fiscal year of adoption. We adopted this standard on January 1, 2020 and the impact that this guidance had on our condensed consolidated financial statements was immaterial.

5. Stockholders’ Equity and Derivative Liability — Warrants

Series A Convertible Preferred Stock

On October 14, 2014, our Board of Directors authorized the sale and issuance of up to 1,250,000 shares of Series A Convertible Preferred Stock (the “Series A”). All shares of the Series A were issued between October 2014 and February 2015. Each share of the Series A is convertible at the option of the holder into the number of shares of common stock determined by dividing the stated value of such share by the conversion price that is subject to adjustment. As of June 30, 2020, there were 85,581 shares outstanding. During the six months ended June 30, 2020, no shares of the Series A were converted.

Series C Convertible Preferred Stock Issuance

On July 3, 2018, we completed a rights offering pursuant to our effective registration statement on Form S-1. We offered for sale units in the rights offering and each unit sold in connection with the rights offering consists of 1 share of our Series C Convertible Preferred Stock, or Series C, and common stock warrants (the “Rights Offering”). Upon completion of the offering, pursuant to the rights offering, we sold an aggregate of 10,826 units at an offering price of $1,000 per unit comprised of 10,826 shares of Series C and 88,928 common stock warrants. As of June 30, 2020,

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

there were 1,827 shares outstanding. During the six months ended June 30, 2020, no shares of the Series C were converted.

Common Stock and Warrant Offering

On October 7, 2015, we entered into an underwriting agreement related to the public offering and sale of 8,929 shares of common stock and warrants to purchase up to 5,357 shares of common stock, at a fixed combined price to the public of $1,680 under our prior shelf registration statement on Form S-3. The shares of common stock and warrants were issued separately on October 13, 2015. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $2,380.00 per share. There is not, nor is there expected to be, any trading market for the warrants issued in the offering contemplated by the Underwriting Agreement.

The gross proceeds to us were $15.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $1.5 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $12.8 million.

If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statements of operations. Upon the issuance of these warrants, the fair value of approximately $4.4 million was recorded as derivative financial instruments liability-warrants.

The fair value of these liability classified warrants was estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of June 30, 2020 and December 31, 2019:


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		0.28	years		0.78	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		140	%		72	%
Dividend yield		—			—

On April 4, 2016, we closed a public offering of 8,803 shares of our common stock and warrants to purchase up to 4,401 shares of common stock, at a fixed combined price to the public of $795.20 under our prior shelf registration statement on Form S-3. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $952.00 per share. The gross proceeds to us were $7.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $0.7 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $4.2 million.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such Fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations. Upon the issuance of these warrants, the fair value of approximately $1.5 million was recorded as derivative financial instruments liability-warrants.


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		0.76	years		1.26	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		128	%		75	%
Dividend yield		—			—

On April 25, 2017, we closed a public offering of 21,429 shares of our common stock and warrants to purchase up to 10,714 shares of common stock, at a fixed combined price to the public of $560.00 under our prior shelf registration statement on Form S-3. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $700.00 per share. The gross proceeds to us were $12.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $0.5 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $7.5 million.

If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations and comprehensive loss. Upon the issuance of these warrants, the fair value of approximately $4.0 million was recorded as derivative financial instruments liability-warrants.

The fair value of these liability classified warrants were estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of June 30, 2020 and December 31, 2019:


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		1.81	years		2.31	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		117	%		69	%
Dividend yield		—			—

The warrants, issued in connection with the July 2018 Rights Offering are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside of our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.

The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of June 30, 2020 and December 31, 2019:


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		3.01	years		3.50	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		119	%		65	%
Dividend yield		—			—

The following table sets forth the components of changes in our derivative financial instruments liability balance for the six months ended June 30, 2020:


		Number of		Derivative
		Warrants		Instrument
Date	Description	Outstanding		Liability
December 31, 2019	Balance of derivative financial instruments liability		107,998	$	5,623
	Change in fair value of warrants for the six months ended June 30, 2020		—		28,775
June 30, 2020	Balance of derivative financial instruments liability		107,998	$	34,398

Common Stock Offering

On February 12, 2020, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc., as agent (“B. Riley FBR”), pursuant to which we may offer and sell, from time to time, through B. Riley FBR, shares of our common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $7,000,000 (the “Shares”).

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

February 6, 2019, as amended on February 13, 2019, and declared effective by the SEC on February 19, 2019, as supplemented by a prospectus supplement dated February 12, 2020 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). Also, on March 27, 2020, we filed a prospectus supplement to the Form S-3 (File No. 333-229534) pursuant to which we may offer and sell an additional $4.6 million.

As of June 30, 2020, under the Sales Agreement we sold 5,262,806 shares of our common stock resulting in net proceeds of $11.2 million from the “at the market offerings”

Pursuant to the Sales Agreement, B. Riley FBR may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made by means of ordinary brokers’ transactions, including on The Nasdaq Capital Market, at market prices or as otherwise agreed with B. Riley FBR. B. Riley FBR will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares from time to time, based upon instructions from us, including any price or size limits or other customary parameters or conditions we may impose.

6. Fair Value Measurements

The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at June 30, 2020 and December 31, 2019.


			Quoted Prices in		Significant
			Active Markets for		Other		Significant
			Identical Assets		Observable		Unobservable
			and Liabilities		Inputs		Inputs
Description	Fair value		(Level 1)		(Level 2)		(Level 3)
As of June 30, 2020:
Contingent consideration	$	2,510,000	$	—	$	—	$	2,510,000
Derivative liabilities related to warrants	$	34,398	$	—	$	—	$	34,398

As of December 31, 2019:
Contingent consideration	$	2,430,000	$	—	$	—	$	2,430,000
Derivative liabilities related to warrants	$	5,623	$	—	$	—	$	5,623

The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities- warrants in our condensed consolidated statement of operations. See Note 5 for a rollfoward of the derivative liability for the six months ended June 30, 2020 . The financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we review the assets and liabilities that are subject to ASC 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

Contingent consideration was recorded for the acquisition of Ciclofilin on June 10, 2016. The contingent consideration represented the acquisition date fair value of potential future payments, to be paid in cash and our stock, upon the achievement of certain milestones and was estimated based on a probability-weighted discounted cash flow model utilizing a discount rate of 6.5% and a stock price of $19.60. We completed the first segment of our Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (Ciclofilin ) and in the fourth quarter of 2018, we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June, 2016, to the Ciclofilin shareholders. As of June 30, 2020, due to the uncertainty in the timing of the clinical development of the associated product candidate, the entire balance is classified as a non-current liability. The following table presents the change in fair value of the contingent consideration for the six months ended June 30, 2020.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

	Acquisition-
	related
	Contingent
	Consideration
Liabilities:
Balance at December 31, 2019	$	2,430,000
Change in fair value recorded in earnings		80,000
Balance at June 30, 2020	$	2,510,000

7. Indefinite-lived Intangible Assets and Goodwill

IPR&D

Our IPR&D asset consisted of the following at:


	Indefinite-lived
	Intangible Asset
CRV431 balance at December 31, 2019	$	3,190,000
Change in fair value during the six months ended June 30, 2020		—
CRV431 balance at June 30, 2020	$	3,190,000

No impairment losses were recorded on IPR&D during the six months ended June 30, 2020 and 2019.

Goodwill

The table below provides a roll-forward of our goodwill balance:


	Amount
Goodwill balance at December 31, 2019	$	1,870,924
Changes during the six months ended June 30, 2020		—
Goodwill balance at June 30, 2020	$	1,870,924

No impairment losses were recorded to goodwill during the six months ended June 30, 2020 and 2019.

8. Accrued Liabilities

Accrued expenses consisted of the following:


	June 30,		December 31,
	2020		2019
Payroll and related costs	$	381,519	$	346,244
Stock-based compensation		390,488		—
Research and development		493,491		12,075
Legal fees		—		2,354
Accrued taxes		89,389		74,357
Other		1,283		58,606
Total accrued expenses	$	1,356,170	$	493,636

9. Accounting for Share-Based Payments

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

authorized shares to 40,535. We granted certain stock option awards during the three months ended June 30, 2020 and at the time that these grants were made, we had 0 shares of common stock available for grant under the Plan. We accounted for the option grants as liability-classified awards requiring us to measure the fair value of the awards each reporting period. The liability related to the awards granted in the three months ended June 30, 2020 in the amount of $0.4 million has been included in accrued expenses in our condensed consolidated balance sheet with the corresponding expense included in our condensed consolidated statements of operations and comprehensive loss. At our annual meeting of stockholders on July 30, 2020, we received shareholder approval to increase the number of shares issuable under the Plan to 2,500,000 from 40,535.

We classify stock-based compensation expense in our condensed consolidated statement of operations in the same way the award recipient's payroll costs are classified or in which the award recipients' service payments are classified. We recorded stock-based compensation expense as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
General and administrative	$	310,718	$	10,377	$	316,628	$	20,742
Research and development		83,893		6,815		86,229		13,956
Total stock-based compensation expense	$	394,611	$	17,192	$	402,857	$	34,698

A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below:


							Weighted
							Average				Weighted Average
	Number of	Exercise Price					Exercise Price		Intrinsic		Remaining
	Options	Per Share					Per Share		Value		Contractual Term
Balance outstanding, December 31, 2019	41,271	$	3.24	-	$	2,452.80	$	194.83	$	43,182	8.42	years
Granted	1,361,500		1.63	-		2.73		1.65		1,647,415
Forfeited	—		—			—		—		—
Cancelled	—		—	-		—		—		—
Balance outstanding, June 30, 2020	1,402,771		3.24	-		2,452.80		7.76		1,641,645	9.72	years
Vested awards and those expected to vest at June 30, 2020	1,339,385		3.24	-		2,452.80		8.04		1,537,890	9.72	years
Vested and exercisable at June 30, 2020	14,530		3.24	-		2,452.80		586.70		—	6.27	years

There were no options granted to employees during the six months ended June 30, 2019. The total fair value of the shares vested during the six months ended June 30, 2019 was de minimis.

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of our common stock for those stock options that had exercise prices lower than the fair value of our common stock.

As of June 30, 2020, the unrecognized compensation cost related to non-vested stock options outstanding, net of expected forfeitures, was $3.3 million to be recognized over a weighted-average remaining vesting period of approximately 2.4 years.

The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate fair value of stock option awards when granted to employees.


	Six Months Ended			Six Months Ended
	June 30, 2020			June 30, 2019
Stock price	$	1.65		$	—
Risk-free interest rate		0.36	%		—	%
Dividend yield		—			—
Expected volatility		126.3	%		—	%
Expected term (in years)		6.00	years		—	years

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Risk-free interest rate—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of our stock options.

Dividend yield— We have not paid any dividends on our common stock since inception and do not anticipate paying dividends on our common stock in the foreseeable future.

Expected volatility—We base expected volatility on the trading price of our common stock.

Expected term—The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in SAB No. 107, which SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at-the-money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable.

In December 2007, the SEC issued SAB No. 110, Share-Based Payment, (“SAB No. 110”). SAB No. 110 was effective January 1, 2008 and expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC 718. We will use the simplified method until we have the historical data necessary to provide a reasonable estimate of expected life in accordance with SAB No. 107, as amended by SAB No. 110. For the expected term, we have “plain-vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107.

Forfeitures—ASC 718 allows for the election of forfeitures to be estimated at the time of grant and revised if necessary, in subsequent periods if actual forfeitures differ from those estimates. At April 1, 2016, we determined that we had sufficient history of issuing stock options and decreased our estimated forfeiture rate from 10%, which was based on the historical experience of our former parent, to 3%, which is our actual historical forfeiture rate. The forfeiture rate was 10% through the end of the 3rd fiscal quarter ended March 31, 2016 and was the adjusted to 3% through the end of the fiscal year June 30, 2016 based on the aforementioned historical analysis. The forfeiture rate was 3% for the six months ended June 30, 2020 and 2019. We will continue to analyze the forfeiture rate on at least an annual basis or when there are any identified triggers that would justify immediate review.

10. Loss per Share

Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with ASC 260, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. In addition, the net loss attributable to common stockholders’ is adjusted for the preferred stock deemed dividends related accretion of beneficial conversion feature and other discount on this instrument for the periods in which the preferred stock is outstanding.

The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:



	Three Months Ended				Six Months Ended
	June 30,				June 30,
Basic and diluted net (loss) income per common share	2020		2019		2020		2019
Numerator:
Net loss	$	(4,940,080)	$	(1,020,898)	$	(9,166,697)	$	(3,004,610)
Preferred stock deemed dividend		—		(5,412,045)		—		(5,436,366)
Net loss attributable to common stockholders	$	(4,940,080)	$	(6,432,943)	$	(9,166,697)	$	(8,440,976)
Denominator:
Weighted average common shares outstanding		8,494,518		859,827		6,420,109		556,662
Net loss per share of common stock—basic and diluted	$	(0.58)	$	(7.48)	$	(1.43)	$	(15.16)

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The following outstanding securities at June 30, 2020 and 2019 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:


	Six Months Ended
	June 30,
	2020	2019
Common shares issuable upon conversion of Series A preferred stock	3,184	3,184
Common shares issuable upon conversion of Series C preferred stock	16,839	16,987
Stock options	1,402,771	9,010
Warrants – liability classified	107,998	107,997
Warrants – equity classified	2,428,568	2,733,076
Total	3,959,360	2,870,254

The liability and equity classified warrants disclosed above have been excluded from the computation of basic and diluted earnings per share because the exercise price of the warrants exceeds the average market price of our common stock for the period they were outstanding.

11. Commitments and Contingencies

Contractual Obligations

In August 2014, we entered into a lease for corporate office space in Edison, New Jersey. In December 2017, we entered an amendment to the lease for corporate office space in Edison, New Jersey expanding the office footprint and extending the lease for an approximate 5-year period. In May 2018, we entered into a 3 year lease for office equipment to be used at our corporate office space in Edison, New Jersey. In October 2019, we entered into a 3 year lease for office and research laboratory space in Edmonton, Canada. Prior to signing this lease, the space was previously on a month to month basis.

Legal Proceedings

We are involved in legal proceedings of various types. Significant judgment is required to determine both the likelihood and the estimated amount of a loss related to such matters. Additionally, while any litigation contains an element of uncertainty, we have at this time no reason to believe that the outcome of such proceedings or claims will have a material adverse effect on our condensed consolidated financial condition or results of operations.

Leases

We account for leases in accordance with ASC Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property or equipment for a period in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property and equipment), and (2) the customer has the right to control the use of the identified asset.

Operating leases where we are the lessee are included under the caption “Right of Use Assets” on our condensed consolidated balance sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. Key estimates and judgments include how we determine (1) the discount rate used to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.

The Right-Of-Use (“ROU”) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

ROU asset of $0.8 million. As of June 30, 2020, the ROU assets are $0.7 million, the current lease liabilities are $0.3 million, and the non-current lease liabilities are $0.5 million. The discount rate used to account for our operating leases under ASC 842 is our estimated incremental borrowing rate of 6.5%.

Rent expense for the three months ended June 30, 2020 and 2019 was $0.1 million and $0.1 million, respectively, and $0.2 million and $0.1 million for the six months ended June 30, 2020 and 2019. The weighted average remaining term of our noncancelable operating leases is 2.63 years. Future minimum rental payments under our noncancelable operating leases at June 30, 2020 is as follows:


2020	$	141,670
2021		285,201
2022		269,751
2023		53,902
2024 and thereafter		—
Total		750,524
Present value adjustment		(57,662)
Lease liability at June 30, 2020	$	692,862

Employment Agreements

We have employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control, termination without cause or retirement, occur.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our condensed consolidated financial statements and other financial information appearing elsewhere in this quarterly report. In addition to historical information, the following discussion and other parts of this quarterly report contain forward-looking statements. You can identify these statements by forward-looking words such as “plan,” “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. Forward-looking statements include information concerning possible or assumed future business success or financial results. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties set forth under “Risk Factors” in our Annual Report on Form 10-K as of and for the year ended December 31, 2019 filed with the United States Securities and Exchange Commission (“SEC”). Accordingly, to the extent that this Report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of us, please be advised that our actual financial condition, operating results and business performance may differ materially from that projected or estimated by us in forward-looking statements, and you should not unduly rely on such statements.

Impact of COVID-19

While we have not experienced delays to date, we may experience delays in the conduct of clinical testing of our product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. The COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidate. The evolving COVID-19 pandemic is also likely to directly or indirectly impact the pace of enrollment in our CRV431 clinical trials for at least the next several months and possibly longer as patients may avoid or may not be able to travel to healthcare facilities and physicians' offices unless due to a health emergency. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial, related to the COVID-19 pandemic, or in obtaining sufficient supplies of clinical trial materials. Any delays in completing our clinical trials will increase our costs, slow down our product development, timeliness and approval process and delay our ability to generate revenue.

Table of Contents

pandemic continues, it could have a material adverse effect on our results of future operations, financial position, liquidity, and capital resources, and those of the third parties on which we rely in fiscal year 2020.

On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), as amended on June 5, 2020 by the Paycheck Protection Program (“PPP”). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. On April 13, 2020, we were granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggregate amount of $176,585, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act. We are continuing to evaluate and examine the impacts the CARES Act may have on our business, results of operations, financial condition or liquidity.

The Loan, which was in the form of a Note dated April 13, 2020 issued by us, matures on April 13, 2022 and bears interest at a rate of 0.98% per annum, payable monthly commencing on November 13, 2020. The Note may be prepaid by us at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, rent and utilities. We intend to use the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. We have a good-faith belief that we properly satisfied all eligibility requirements for the PPP loan and we intend to comply with the loan forgiveness provisions in the legislation; however, there can be no assurance that we will obtain full forgiveness of the loans based on the legislation. The PPP Loan is reflected in the condensed consolidated balance sheet as long-term debt based upon the terms and conditions of the Loan agreement.

Business Overview

We are a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease.

NASH is the form of liver disease that is triggered by what has come to be known as the “Western diet”, characterized especially by high-fat, high-sugar, and processed foods. Among the effects of a prolonged Western diet is fat accumulation in liver cells (steatosis) which is described as non-alcoholic fatty liver disease (“NAFLD”) and can predispose cells to injury. NAFLD may evolve into NASH when the fatty liver begins to progress through stages of cell injury, inflammation, fibrosis, and carcinogenesis. People who develop NASH often have additional predisposing conditions such as diabetes and hypertension, but the exact biochemical events that trigger and maintain the progression are not well known. Many people in the early stages of disease do not have significant symptoms and therefore do not know that they have it. NASH becomes evident and a major concern when the liver becomes fibrotic and puts the individual at increased risk of developing cirrhosis and other complications. Individuals with advanced liver fibrosis have significantly higher risk of developing liver cancer, although cancer may also arise in some patients before significant hepatitis or fibrosis. NASH is increasing worldwide at an alarming rate due to the spread of the Western diet, obesity, and other related conditions. Approximately 4-5% of the global population is estimated to have NASH, and that proportion is higher in the USA. Considering the serious outcomes linked to advancing NASH, the economic and social burden of the disease is enormous. There are no simple blood tests to diagnose or track the progression of NASH, and no drugs are approved to specifically treat the disease.

FINANCIAL OPERATIONS OVERVIEW

From inception through June 30, 2020, we have an accumulated deficit of $92.3 million and we have not generated any revenue from operations and expect to incur additional losses to perform further research and development

Table of Contents

activities and do not currently have any commercial biopharmaceutical products. We do not expect to have such for several years, if at all.

The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-229534) filed by us with the Securities and Exchange Commission (the “SEC”) on February 6, 2019, as amended on February 13, 2019, and declared effective by the SEC on February 19, 2019, as supplemented by a prospectus supplement dated February 12, 2020 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). Also, on March 27, 2020, we filed a prospectus supplement to the Form S-3 (File No. 333-229534) pursuant to which we may offer and sell an additional $4.6 million.

As of June 30, 2020, under the Sales Agreement we sold 5,264,806 shares of our common stock resulting in net proceeds of $11.2 million from the “at the market offerings”

Our product development efforts are in their early stages and we cannot make estimates of the costs or the time they will take to complete. The risk of completion of any program is high because of the many uncertainties involved in bringing new drugs to market including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, the extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses and competing technologies being developed by organizations with significantly greater resources.

CRITICAL ACCOUNTING POLICIES

Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses, income taxes and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

During the six months ended June 30, 2020, there were no significant changes to our critical accounting policies and estimates as described in the financial statements contained in the Annual Report on Form 10-K for the year ended December 31, 2019.

OFF-BALANCE SHEET ARRANGEMENTS

We had no off-balance sheet arrangements as of June 30, 2020.

RECENT ACCOUNTING PRONOUNCEMENTS

Please refer to Note 4 of Notes to Condensed Consolidated Financial Statements, Recent Accounting Pronouncements, in this Quarterly Report on Form 10-Q.

JOBS Act

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:

Table of Contents

●

requirement to provide only two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;

●

reduced disclosure about our executive compensation arrangements;

●

no non-binding advisory votes on executive compensation or golden parachute arrangements; and

●

exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.

We have irrevocably elected not to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act, and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We may take advantage of these provisions up to the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement or such earlier time that we are no longer an emerging growth company. We could remain an “emerging growth company” until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the first public sale of equity securities in October 2015, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeded $700.0 million as of the prior December 31st, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

To the extent that we continue to qualify as a “smaller reporting company,” as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures; and (3) the requirement to provide only two years of audited financial statements, instead of three years.

RESULTS OF OPERATIONS

Comparison of the three months ended June 30, 2020 and 2019:


	Three Months Ended
	June 30,
	2020		2019		Change
Revenues	$	—	$	—	$	—
Costs and Expenses:
Research and development		2,950,340		755,659		2,194,681
General and administrative		1,825,074		939,909		885,165
Loss from operations		(4,775,414)		(1,695,568)		(3,079,846)

Other income (expense):
Change in fair value of debt		—		(94,154)		94,154
Interest expense		—		(441,801)		441,801
Change in fair value of derivative instruments – warrants and contingent consideration		(69,095)		249,611		(318,706)
Loss before income taxes		(4,844,509)		(1,981,912)		(2,862,597)
Income tax (expense) benefit		(95,571)		961,014		(1,056,585)
Net loss	$	(4,940,080)	$	(1,020,898)	$	(3,919,182)

We had no revenues during the three months ended June 30, 2020 and 2019, respectively, because we do not have any commercial biopharmaceutical products and we do not expect to have such products for several years, if at all.

Research and development expenses for the three months ended June 30, 2020 and 2019 was $3.0 million and $0.8 million, respectively. The $2.2 million increase was primarily due to an increase of $0.9 million for costs related to drug supply and various ongoing studies, a $0.5 million increase attributable to the phase 1 and phase 2 studies related to CRV431 and a $0.3 million increase in consulting costs.

Table of Contents

General and administrative expenses for the three months ended June 30, 2020 and 2019 was $1.8 million and $0.9 million, respectively. The increase of $0.9 million is primarily related to an increase of $0.1 million in insurance costs, a $0.3 million increase in stock-based compensation costs, and a $0.2 million increase in professional fees and consulting costs.

Net loss for the three months ended June 30, 2020 was $4.9 million, which was the result of the operating expenses discussed above, a decrease of $0.1 million for the change in fair value of derivative instruments related to our warrants and contingent consideration and $0.1 million for income tax expense. Net loss for the three months ended June 30, 2019 was $1.0 million, which was the result of the operating expenses discussed above, a loss of $0.1 million for the change in fair value of debt, a $0.4 million loss for interest expense, which was offset by income of $0.2 million resulting from the change in fair value of derivative instruments related to our warrants and contingent consideration and $1.0 million for income tax benefit.

Comparison of the six months ended June 30, 2020 and 2019:


	Six Months Ended
	June 30,
	2020		2019		Change
Revenues	$	—	$	—	$	—
Costs and Expenses:
Research and development		5,587,671		1,273,699		4,313,972
General and administrative		3,374,680		2,343,570		1,031,110
Loss from operations		(8,962,351)		(3,617,269)		(5,345,082)

Other income (expense):
Change in fair value of debt		—		(153,795)		153,795
Interest expense		—		(540,088)		540,088
Change in fair value of derivative instruments – warrants and contingent consideration		(108,775)		345,528		(454,303)
Loss before income taxes		(9,071,126)		(3,965,624)		(5,105,502)
Income tax (expense) benefit		(95,571)		961,014		(1,056,585)
Net loss	$	(9,166,697)	$	(3,004,610)	$	(6,162,087)

We had no revenues during the six months ended June 30, 2020 and 2019, respectively, because we do not have any commercial biopharmaceutical products and we do not expect to have such products for several years, if at all.

Research and development expenses for the six months ended June 30, 2020 and 2019 was $5.6 million and $1.3 million, respectively. The $4.3 million increase was primarily due to an increase of $1.6 million for costs related to drug supply, a $0.9 million increase attributable to the phase 1 and phase 2 studies related to CRV431 and a $1.2 million increase in consulting costs.

General and administrative expenses for the six months ended June 30, 2020 and 2019 was $3.4 million and $2.3 million, respectively. The $1.1 million increase was primarily related to an increase in insurance costs of $0.1 million, an increase of $0.3 million in stock-based compensation costs and a $0.2 million increase in professional fees.

Net loss for the six months ended June 30, 2020 was $9.2 million, which was the result of the operating expenses discussed above, a decrease of $0.1 million for the change in fair value of derivative instruments related to our warrants and contingent consideration and $0.1 million for income tax expense. Net loss for the six months ended June 30, 2019 was $3.0 million, which was the result of the operating expenses discussed above, a loss of $0.2 million for the change in fair value of debt, a $0.5 million loss for interest expense, which was offset by income of $0.3 million resulting from the change in fair value of derivative instruments related to our warrants and contingent consideration and $1.0 million for income tax benefit.

Liquidity and Capital Resources

As of June 30, 2020, we had working capital of $15.6 million compared to working capital of $13.1 million as of December 31, 2019. The increase of $2.5 million in working capital is primarily related to a net increase in cash of $3.7 million.

Table of Contents

Cash Flows

The following table summarizes our cash flows for the following periods:


	Six Months Ended
	June 30,
	2020		2019
Net cash provided by (used in):
Operating activities	$	(7,789,316)	$	(3,321,963)
Investing activities		(9,242)		(45,334)
Financing activities		11,437,399		17,683,928
Net increase in cash	$	3,638,841	$	14,316,631

As of June 30, 2020, we had $17.6 million in cash. Net cash used in operating activities was $7.8 million for the six months ended June 30, 2020 consisting primarily of our net loss of $9.2 million. Changes in working capital accounts had a positive impact of $0.8 million on cash primarily for an increase in accounts payable and accrued expenses.

Net cash used in operating activities was $3.3 million for the six months ended June 30, 2019 consisting primarily of our net loss of $3.0 million and non-cash operating activities of $0.4 million. Changes in working capital accounts had a negative impact of $0.7 million on cash.

Net cash used in investing activities during the six months ended June 30, 2020 and 2019 was immaterial in both periods.

Net cash provided by financing activities was $11.4 million for the six months ended June 30, 2020 due primarily to the issuance of common stock, net of issuance costs.

Net cash provided by financing activities was $17.7 million for the six months ended June 30, 2019 due primarily to the issuance of preferred stock for $10.1 million, $2.1 million for the exercise of warrants and $5.8 million for the issuance of common stock.

Operating and Capital Expenditure Requirements

As of June 30, 2020, we had an accumulated deficit of $92.3 million and expect to incur a significant increase in operating losses for the next several years as we expand our research, development and clinical trials of CRV431. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

The condensed consolidated financial statements as of June 30, 2020 have been prepared under the assumption that we will continue as a going concern within one year after the financial statements are issued. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. Recently worldwide economic conditions and the international equity and credit markets have significantly deteriorated and may remain difficult for the foreseeable future. These developments will make it more difficult to obtain additional equity or credit financing, when needed. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct, delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.

Table of Contents

Contractual Obligations and Commitments

Please refer to Note 11 of Notes to Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for a description of our contractual obligations and commitments.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures. Based on an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) required by paragraph (b) of Rule 13a-15 or Rule 15d-15, as of June 30, 2020, our Principal Executive Officer and Principal Financial Officer have concluded that, due to the material weaknesses in our internal control over financial reporting, our disclosure controls and procedures were not effective.

Changes in Internal Control over Financial Reporting

As required by Rule 13a-15(d) of the Exchange Act, our management, including our principal executive officer and our principal financial officer, conducted an evaluation of the internal control over financial reporting to determine whether any changes occurred during the quarter ended June 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. There have been no changes in our internal controls over financial reporting during the three months ended June 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are committed to the remediation of the material weaknesses described in our Annual Report on Form 10-K, as well as the continued improvement of our internal control over financial reporting. We are in the process of taking steps to remediate the identified material weaknesses and continue to evaluate our internal controls over financial reporting, including the following:

●

We assessed our companywide accounting resource requirements and as a result have hired, and are in the process of hiring additional experienced accounting personnel, and taken steps to improve the overall efficiency of our accounting and reporting processes. We will continue to regularly monitor our accounting resource sufficiency, our internal controls processes and procedures, and we may undertake additional measures as deemed necessary to fully remediate the control deficiencies.

●

We have implemented several software solutions to improve our financial reporting process.

●

We are utilizing the services of external consultants for non-routine and\or technical accounting issues as they arise.

As we continue our evaluation and improve our internal control over financial reporting, management may identify and take additional measures to address control deficiencies. We cannot assure you that we will be successful in remediating the material weaknesses in a timely manner.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS

There have been no material changes to the Risk Factors we previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.

ITEM 6. EXHIBITS


31.1		Certification of Chief Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
31.2		Certification of Principal Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

20
	HEPION PHARMACEUTICALS, INC. (Registrant)

Date: 08/12/2020	By:	/s/ ROBERT FOSTER
		Robert Foster
		Chief Executive Officer
		(Principal Executive Officer)

Date: 08/12/2020	By:	/s/ JOHN CAVAN
		John Cavan
		Chief Financial Officer

EX-31.1 2 hepa-20200630ex31134cbda.htm EX-31.1

EXHIBIT 31.1

CERTIFICATIONS

I, Robert Foster, certify that:

1)I have reviewed this report on Form 10-Q of Hepion Pharmaceuticals, Inc.

2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 12, 2020	/s/ Robert Foster
	Robert Foster
	Chief Executive Officer and Director (Principal Executive Officer)

EX-31.2 3 hepa-20200630ex31233a606.htm EX-31.2

EXHIBIT 31.2

CERTIFICATIONS

I, John Cavan, certify that:

1)I have reviewed this report on Form 10-Q of Hepion Pharmaceuticals, Inc.

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 12, 2020	/s/ John Cavan
	John Cavan
	Chief Financial Officer

EX-32.1 4 hepa-20200630ex321cba7bf.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

HEPION PHARMACEUTICALS, INC.

FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2020

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I am the Chief Executive Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended June 30, 2020 and filed with the Securities and Exchange Commission (“Form 10-Q”).

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 12, 2020	/s/ Robert Foster
	Robert Foster
	Chief Executive Officer and Director (Principal Executive Officer)

EX-32.2 5 hepa-20200630ex3226e08b6.htm EX-32.2

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

HEPION PHARMACEUTICALS, INC.

FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2020

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I am the Chief Financial Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended June 30, 2020 and filed with the Securities and Exchange Commission (“Form 10-Q”).


Date: August 12, 2020	/s/ John Cavan
	John Cavan
	Chief Financial Officer

GRAPHIC 6 hepa-20200630x10q002.jpg GRAPHIC begin 644 hepa-20200630x10q002.jpg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hepa-20200630.xml EX-101.INS 0001583771 hepa:October132015Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-06-30 0001583771 hepa:October132015Member us-gaap:MeasurementInputPriceVolatilityMember 2020-06-30 0001583771 hepa:October132015Member us-gaap:MeasurementInputExpectedTermMember 2020-06-30 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-06-30 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputPriceVolatilityMember 2020-06-30 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputExpectedTermMember 2020-06-30 0001583771 hepa:April42016Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-06-30 0001583771 hepa:April42016Member us-gaap:MeasurementInputPriceVolatilityMember 2020-06-30 0001583771 hepa:April42016Member us-gaap:MeasurementInputExpectedTermMember 2020-06-30 0001583771 hepa:April252017Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-06-30 0001583771 hepa:April252017Member us-gaap:MeasurementInputPriceVolatilityMember 2020-06-30 0001583771 hepa:April252017Member us-gaap:MeasurementInputExpectedTermMember 2020-06-30 0001583771 hepa:October132015Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001583771 hepa:October132015Member us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001583771 hepa:October132015Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001583771 hepa:April42016Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001583771 hepa:April42016Member us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001583771 hepa:April42016Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001583771 hepa:April252017Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001583771 hepa:April252017Member us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001583771 hepa:April252017Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001583771 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2019-04-01 2019-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001583771 us-gaap:PrivatePlacementMember 2019-04-01 2019-06-30 0001583771 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2019-01-01 2019-03-31 0001583771 us-gaap:PrivatePlacementMember 2019-01-01 2019-03-31 0001583771 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001583771 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001583771 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001583771 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2019-01-01 2019-03-31 0001583771 us-gaap:SeriesCPreferredStockMember 2018-07-03 2018-07-03 0001583771 us-gaap:RetainedEarningsMember 2020-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001583771 us-gaap:RetainedEarningsMember 2020-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001583771 2020-03-31 0001583771 us-gaap:RetainedEarningsMember 2019-12-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001583771 us-gaap:RetainedEarningsMember 2019-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001583771 us-gaap:RetainedEarningsMember 2019-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001583771 2019-03-31 0001583771 us-gaap:RetainedEarningsMember 2018-12-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0001583771 us-gaap:CommonStockMember 2020-06-30 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001583771 us-gaap:CommonStockMember 2020-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001583771 us-gaap:CommonStockMember 2019-12-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-06-30 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-06-30 0001583771 us-gaap:CommonStockMember 2019-06-30 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-03-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-03-31 0001583771 us-gaap:CommonStockMember 2019-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001583771 us-gaap:CommonStockMember 2018-12-31 0001583771 hepa:October132015Member 2020-06-30 0001583771 hepa:July3rd2018Member 2020-06-30 0001583771 hepa:April42016Member 2020-06-30 0001583771 hepa:April252017Member 2020-06-30 0001583771 hepa:October132015Member 2019-12-31 0001583771 hepa:July3rd2018Member 2019-12-31 0001583771 hepa:April42016Member 2019-12-31 0001583771 hepa:April252017Member 2019-12-31 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeTwoMember 2020-01-01 2020-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeOneMember 2020-01-01 2020-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeOneMember 2019-01-01 2019-12-31 0001583771 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001583771 us-gaap:EmployeeStockOptionMember 2019-12-31 0001583771 srt:ScenarioForecastMember us-gaap:StockCompensationPlanMember 2020-07-31 0001583771 us-gaap:StockCompensationPlanMember 2018-02-21 0001583771 us-gaap:StockCompensationPlanMember 2016-12-14 0001583771 us-gaap:StockCompensationPlanMember 2014-12-02 0001583771 us-gaap:StockCompensationPlanMember 2013-06-03 2013-06-03 0001583771 us-gaap:StockCompensationPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001583771 us-gaap:StockCompensationPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001583771 us-gaap:StockCompensationPlanMember 2020-04-01 2020-06-30 0001583771 us-gaap:StockCompensationPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001583771 us-gaap:StockCompensationPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001583771 us-gaap:StockCompensationPlanMember 2020-01-01 2020-06-30 0001583771 us-gaap:StockCompensationPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001583771 us-gaap:StockCompensationPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001583771 us-gaap:StockCompensationPlanMember 2019-04-01 2019-06-30 0001583771 us-gaap:StockCompensationPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001583771 us-gaap:StockCompensationPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001583771 us-gaap:StockCompensationPlanMember 2019-01-01 2019-06-30 0001583771 hepa:CiclofilinPharmaceuticalsInc.Member 2016-06-01 2016-06-30 0001583771 srt:MinimumMember 2020-01-01 2020-06-30 0001583771 srt:MaximumMember 2020-01-01 2020-06-30 0001583771 2019-01-01 2019-12-31 0001583771 hepa:AtMarketIssuanceSalesAgreementMember 2020-03-27 2020-03-27 0001583771 hepa:AtMarketIssuanceSalesAgreementMember 2020-01-01 2020-06-30 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-07-03 0001583771 us-gaap:SeriesAPreferredStockMember 2014-10-14 0001583771 us-gaap:SeriesCPreferredStockMember 2019-12-31 0001583771 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001583771 us-gaap:SeriesCPreferredStockMember 2018-07-03 0001583771 us-gaap:StockCompensationPlanMember 2020-06-30 0001583771 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001583771 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001583771 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001583771 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001583771 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001583771 hepa:OfficeAndResearchLaboratoryMember 2019-10-31 0001583771 us-gaap:OfficeEquipmentMember 2018-05-31 0001583771 hepa:OfficeSpaceMember 2017-12-31 0001583771 2019-04-01 2019-04-30 0001583771 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-06-30 0001583771 us-gaap:FairValueInputsLevel3Member hepa:ContingentConsiderationMember 2020-06-30 0001583771 us-gaap:FairValueInputsLevel3Member hepa:ContingentConsiderationMember 2019-12-31 0001583771 us-gaap:FairValueInputsLevel3Member hepa:ContingentConsiderationMember 2020-01-01 2020-06-30 0001583771 hepa:October132015Member 2020-01-01 2020-06-30 0001583771 hepa:July3rd2018Member 2020-01-01 2020-06-30 0001583771 hepa:April42016Member 2020-01-01 2020-06-30 0001583771 hepa:April252017Member 2020-01-01 2020-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2020-06-30 0001583771 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0001583771 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001583771 hepa:April252017Member us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2017-04-25 0001583771 hepa:April42016Member us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2016-04-04 0001583771 hepa:October132015Member us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2015-10-13 0001583771 hepa:PaycheckProtectionProgramLoanMember 2020-04-13 0001583771 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001583771 us-gaap:SeriesCPreferredStockMember 2020-06-30 0001583771 us-gaap:SeriesAPreferredStockMember 2020-06-30 0001583771 us-gaap:SeriesCPreferredStockMember 2019-01-01 2019-06-30 0001583771 hepa:AtMarketIssuanceSalesAgreementMember 2020-02-12 0001583771 us-gaap:WarrantMember 2020-06-30 0001583771 us-gaap:WarrantMember 2019-12-31 0001583771 hepa:April252017Member us-gaap:WarrantMember 2017-04-25 0001583771 hepa:April42016Member us-gaap:WarrantMember 2016-04-04 0001583771 hepa:October132015Member us-gaap:WarrantMember 2015-10-13 0001583771 2019-06-30 0001583771 2018-12-31 0001583771 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001583771 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001583771 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001583771 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001583771 us-gaap:MeasurementInputSharePriceMember 2016-06-10 0001583771 us-gaap:MeasurementInputDiscountRateMember 2016-06-10 0001583771 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001583771 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-06-30 0001583771 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001583771 hepa:WarrantsLiabilityMember 2020-01-01 2020-06-30 0001583771 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001583771 us-gaap:SeriesCPreferredStockMember 2019-01-01 2019-06-30 0001583771 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001583771 hepa:WarrantsLiabilityMember 2019-01-01 2019-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001583771 2019-01-01 2019-03-31 0001583771 us-gaap:WarrantMember 2018-07-03 2018-07-03 0001583771 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001583771 2020-01-01 2020-03-31 0001583771 hepa:CiclofilinPharmaceuticalsInc.Member 2018-10-01 2018-10-31 0001583771 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001583771 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001583771 2016-04-01 2016-04-01 0001583771 2016-04-01 2016-12-31 0001583771 2016-04-01 2016-06-30 0001583771 2016-01-01 2016-03-31 0001583771 2020-06-30 0001583771 hepa:April42016Member 2016-04-04 2016-04-04 0001583771 hepa:October132015Member 2015-10-13 2015-10-13 0001583771 us-gaap:SeriesEPreferredStockMember 2019-01-01 2019-06-30 0001583771 us-gaap:SeriesDPreferredStockMember 2019-01-01 2019-06-30 0001583771 2019-12-31 0001583771 hepa:April252017Member 2017-04-25 2017-04-25 0001583771 hepa:April252017Member 2017-04-25 0001583771 hepa:April42016Member 2016-04-04 0001583771 hepa:October132015Member 2015-10-13 0001583771 2020-04-01 2020-06-30 0001583771 2019-04-01 2019-06-30 0001583771 hepa:AtMarketIssuanceSalesAgreementMember 2020-02-12 2020-02-12 0001583771 hepa:April252017Member us-gaap:WarrantMember 2017-04-25 2017-04-25 0001583771 hepa:April42016Member us-gaap:WarrantMember 2016-04-04 2016-04-04 0001583771 hepa:October132015Member us-gaap:WarrantMember 2015-10-13 2015-10-13 0001583771 2019-01-01 2019-06-30 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001583771 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001583771 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001583771 2020-08-05 0001583771 2020-01-01 2020-06-30 hepa:segment xbrli:pure iso4217:USD xbrli:shares iso4217:USD xbrli:shares false --12-31 Q2 2020 2020-06-30 10-Q 0001583771 9025153 Yes true true Non-accelerated Filer Yes HEPION PHARMACEUTICALS, INC. false true -768042 186692 581350 -24321 24321 -4642124 44941 286176 4311007 692918 <div> <div> 2. Basis of Presentation and Going Concern    These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2019 was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 contained in our Annual Report on Form 10-K.   Principles of Consolidation   The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation.   Going Concern   As of June 30, 2020, we had $17.6 million in cash, we had an accumulated deficit of $92.3 million, and we had working capital of $15.6 million. For the six months ended June 30, 2020 cash used in operating activities was $7.8 million and for the three and six months ended June 30, 2020 we had a net loss of $4.9 million and $9.2 million, respectively. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through issuances of convertible debt, common stock and preferred stock. We expect to continue to incur losses for the next several years as we expand our research, development and clinical trials of CRV431. We are unable to predict the extent of any future losses or when we will become profitable, if at all.   These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. These condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.   We will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.   COVID-19 Pandemic   On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.   The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation and its impact on our financial condition, liquidity, operations, suppliers, industry, and workforce.   While we have not experienced delays to date,  we may experience delays in the conduct of clinical testing of our product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. The COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidate. The evolving COVID-19 pandemic is also likely to directly or indirectly impact the pace of enrollment in our CRV431 clinical trials for at least the next several months and possibly longer as patients may avoid or may not be able to travel to healthcare facilities and physicians' offices unless due to a health emergency. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial, related to the COVID-19 pandemic, or in obtaining sufficient supplies of clinical trial materials. Any delays in completing our clinical trials will increase our costs, slow down our product development, timeliness and approval process and delay our ability to generate revenue.   The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change and we do not yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. Although we cannot estimate the length or gravity of the impact of the COVID-19 outbreak nor estimate the potential impact to our fiscal year 2020 financial statements at this time, if the pandemic continues, it could have a material adverse effect on our results of future operations, financial position, liquidity, and capital resources, and those of the third parties on which we rely in fiscal year 2020.   On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), as amended on June 5, 2020 by the Paycheck Protection Program (“PPP”). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. On April 13, 2020, we were granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggregate amount of $176,585, pursuant to the PPP under Division A, Title I of the CARES Act. We are continuing to evaluate and examine the impacts the CARES Act may have on our business, results of operations, financial condition or liquidity.    The Loan, which was in the form of a Note dated April 13, 2020 issued by us, matures on April 13, 2022 and bears interest at a rate of 0.98% per annum, payable monthly commencing on November 13, 2020. The Note may be prepaid by us at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, rent and utilities. We intend to use the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. We have a good-faith belief that we properly satisfied all eligibility requirements for the PPP loan and we intend to comply with the loan forgiveness provisions in the legislation; however, there can be no assurance that we will obtain full forgiveness of the loan based on the legislation. The PPP Loan is reflected in the condensed consolidated balance sheet as long-term debt based upon the terms and conditions of the Loan agreement. <div /></div> </div> <div> <div> <a name="NotestoConsolidatedFinancialStatements_4"></a>1. Business Overview   Hepion Pharmaceuticals, Inc. (we, our, or us) is a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease.   On July 18, 2019, we filed a certificate of amendment (the “Certificate of Amendment”) to our certificate of incorporation (the “Certificate”) to change our name from “ContraVir Pharmaceuticals, Inc.” to “Hepion Pharmaceuticals, Inc.” The name change became effective as of July 18, 2019.   We are developing CRV431 as our lead molecule. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. To date, in vitro and/or in vivo studies have demonstrated reductions in HBV DNA, HBsAg, HBeAg, inhibition of virus uptake (NTCP transport inhibition), and stimulation of innate immunity. Importantly, in vivo studies in a NASH model of fibrosis and HCC have repeatedly demonstrated CRV431 reduces fibrosis scores and overall liver tumor burden. Hence, CRV431 is a pleiotropic molecule that may not only treat liver disease but may also serve to reduce important risk factors (e.g., HBV) for developing the disease. We have completed a phase 1 study with CRV431 demonstrating safety, tolerability, and pharmacokinetics (PK).   CRV431   On May 10, 2018, we submitted an Investigational New Drug Application (“IND”) to the U.S. Food and Drug Administration (“FDA”) to support initiation of our CRV431 HBV clinical development program in the United States and received approval in June 2018. We completed the first segment of Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (“Ciclofilin”) and we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June 2016, to the Ciclofilin shareholders.   On June 17, 2019, we submitted an IND to the FDA to support initiation of our CRV431 NASH clinical development program in the United States and received approval in July 2019. <div /></div> </div> 153795 P5Y P5Y P5Y 7000000 -153795 -94154 345528 249611 -108775 -69095 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Derivative </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Instrument </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Date </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Liability </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2019 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance of derivative financial instruments liability </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value of warrants for the six months ended June 30, 2020 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 28,775 </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance of derivative financial instruments liability </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34,398 </td> </tr> </table></div>   <div /></div> </div> 1680 795.20 560.00 P90D P90D P90D 2354 49729 768042 -186692 -581350 403120 9649258 12800000 4200000 7500000 12075 493491 <div> <div> The following table presents the change in fair value of the contingent consideration for the six months ended June 30, 2020.       <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Acquisition- </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> related </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contingent </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Consideration </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liabilities: </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at December 31, 2019 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Change in fair value recorded in earnings </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at June 30, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,510,000 </td> </tr> </table></div>   <div /></div> </div> 0.10 0.03 0.03 0.03 0.03 0.10 1647415 390488 248877 2000 55398 55398 2090567 2090542 25 12000 12000 293145 5357 4401 10714 88928 15600000

<div> <div> 8. Accrued Liabilities Accrued expenses consisted of the following: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Payroll and related costs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 381,519 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 346,244 </td> </tr> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock-based compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 390,488 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 493,491 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12,075 </td> </tr> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Legal fees </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,354 </td> </tr> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued taxes </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 89,389 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 74,357 </td> </tr> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,283 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 58,606 </td> </tr> <tr> <td valign="bottom" style="width:75.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total accrued expenses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,356,170 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 493,636 </td> </tr> </table></div>   <div /></div> </div>

491557

972362

493636

1356170

97651006

108923663

17506

17133

8246

4123

-1038624

-536787

-29526

-472311

293145

-48250

-244895

486612

2870254

107997

9010

3184

16987

2733076

3959360

107998

1402771

3184

16839

2428568

20432607

24083632

14388665

18168939

50000

80000

6.5

19.60

2430000

2510000

13922972

13900000

17600000

17561813

<div> <div> Cash   As of June 30, 2020 and December 31, 2019, cash was $17.6 million and $13.9 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced losses related to these balances. <div /></div> </div>

2832429

17149060

13922972

17561813

14316631

3638841

2380.00

952.00

700.00

107998

<div> <div> 11. Commitments and Contingencies   Contractual Obligations In August 2014, we entered into a lease for corporate office space in Edison, New Jersey. In December 2017, we entered an amendment to the lease for corporate office space in Edison, New Jersey expanding the office footprint and extending the lease for an approximate 5-year period. In May 2018, we entered into a 3 year lease for office equipment to be used at our corporate office space in Edison, New Jersey. In October 2019, we entered into a 3 year lease for office and research laboratory space in Edmonton, Canada. Prior to signing this lease, the space was previously on a month to month basis. Legal Proceedings We are involved in legal proceedings of various types. Significant judgment is required to determine both the likelihood and the estimated amount of a loss related to such matters. Additionally, while any litigation contains an element of uncertainty, we have at this time no reason to believe that the outcome of such proceedings or claims will have a material adverse effect on our condensed consolidated financial condition or results of operations. Leases We account for leases in accordance with ASC Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property or equipment for a period in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property and equipment), and (2) the customer has the right to control the use of the identified asset. Operating leases where we are the lessee are included under the caption “Right of Use Assets” on our condensed consolidated balance sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. Key estimates and judgments include how we determine (1) the discount rate used to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments. The Right-Of-Use (“ROU”) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We adopted ASC 842 in the first quarter of 2019 using an alternative modified retrospective approach, in which prior periods will not be restated. As a result of the adoption, as of January 1, 2019, we recognized an operating lease liability of $0.8 million based on the present value of the minimum rental payments of the leases and a corresponding ROU asset of $0.8 million. As of June 30, 2020, the ROU assets are $0.7 million, the current lease liabilities are $0.3 million, and the non-current lease liabilities are $0.5 million. The discount rate used to account for our operating leases under ASC 842 is our estimated incremental borrowing rate of 6.5%. Rent expense for the three months ended June 30, 2020 and 2019 was $0.1 million and $0.1 million, respectively, and $0.2 million and $0.1 million for the six months ended June 30, 2020 and 2019. The weighted average remaining term of our noncancelable operating leases is 2.63 years. Future minimum rental payments under our noncancelable operating leases at June 30, 2020 is as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 141,670 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 285,201 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 269,751 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 53,902 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2024 and thereafter </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 750,524 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Present value adjustment </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (57,662) </td> </tr> <tr> <td valign="top" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Lease liability at June 30, 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 692,862 </td> </tr> </table></div> Employment Agreements   We have employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control, termination without cause or retirement, occur. <div /></div> </div>

<div> <div> Contingencies   In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized. <div /></div> </div>

0.0001

120000000

3760255

9025061

3760255

9025061

375

901

131000

521000

10570002

400000

149918

149917

400063

400059

11882

42439

176585

768042

18752

49177

12928

8287

13729

7202

5623

34398

4400000

1500000

4000000

5623

34398

<div> <div> Derivative Financial Instruments    We have issued common stock warrants in connection with the execution of certain equity financings. The fair value of the warrants, which were deemed to be derivative instruments based on certain contingent put features, was recorded as a derivative liability under the provisions of ASC Topic 815 Derivatives and Hedging (“ASC 815”) upon issuance. Subsequently, the liability is adjusted to fair value as of the end of each reporting period and the changes in the fair value of derivative liabilities are recorded in the statements of operations under the caption “Change in fair value of derivative financial instruments—warrants.” See Note 5 for additional information.   The fair value of the warrants, issued in connection with the October 2015, April 2016, and April 2017 common stock offerings were deemed to be derivative instruments due to certain contingent put features, was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The warrants, issued in connection with the July 2018 Rights Offering (See Note 5) are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The fair value of warrants was affected by changes in inputs to the Black-Scholes option pricing model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. This model uses Level 3 inputs, including stock price volatility, in the fair value hierarchy established by ASC 820 Fair Value Measurement. At June 30, 2020 and December 31, 2019, the fair value of all warrants was $34,398 and $5,623, respectively, which are classified as a long-term derivative liability on our condensed consolidated balance sheets. <div /></div> </div>

<div> <div> 9. Accounting for Share‑Based Payments On June 3, 2013, we adopted the 2013 Equity Incentive Plan (the “Plan”). Stock options granted under the Plan typically will vest after three years of continuous service from the grant date and will have a contractual term of ten years. Stockholder and Board approval was obtained on December 2, 2014 to increase the number of authorized shares to 11,607 and on December 14, 2016, Stockholder and Board approval was obtained to increase the number of authorized shares to 13,750. Stockholder and Board approval was obtained on February 21, 2018 to increase the number of authorized shares to 40,535. We granted certain stock option awards during the three months ended June 30, 2020 and at the time that these grants were made, we had 0 shares of common stock available for grant under the Plan. We accounted for the option grants as liability-classified awards requiring us to measure the fair value of the awards each reporting period. The liability related to the awards granted in the three months ended June 30, 2020 in the amount of $0.4 million has been included in accrued expenses in our condensed consolidated balance sheet with the corresponding expense included in our condensed consolidated statements of operations and comprehensive loss. At our annual meeting of stockholders on July 30, 2020, we received shareholder approval to increase the number of shares issuable under the Plan  to 2,500,000 from 40,535. We classify stock-based compensation expense in our condensed consolidated statement of operations in the same way the award recipient's payroll costs are classified or in which the award recipients' service payments are classified. We recorded stock-based compensation expense as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:18.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:58.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:18.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> </tr> <tr> <td valign="bottom" style="width:58.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:58.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 310,718 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,377 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 316,628 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,742 </td> </tr> <tr> <td valign="bottom" style="width:58.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 83,893 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,815 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 86,229 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,956 </td> </tr> <tr> <td valign="bottom" style="width:58.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation expense </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 394,611 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17,192 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 402,857 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34,698 </td> </tr> <tr> <td valign="bottom" style="width:58.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 101.28%;"> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted Average </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:15.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Per Share </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Per Share </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Term </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance outstanding, December 31, 2019 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,271 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 194.83 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43,182 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.42 </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,361,500 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.63 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.73 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,647,415 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cancelled </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance outstanding, June 30, 2020 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,402,771 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.76 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,641,645 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.72 </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested awards and those expected to vest at June 30, 2020 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,339,385 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8.04 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,537,890 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9.72 </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested and exercisable at June 30, 2020 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,530 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 586.70 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.27 </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> </table></div> There were no options granted to employees during the six months ended June 30, 2019. The total fair value of the shares vested during the six months ended June 30, 2019 was de minimis. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of our common stock for those stock options that had exercise prices lower than the fair value of our common stock. As of June 30, 2020, the unrecognized compensation cost related to non-vested stock options outstanding, net of expected forfeitures, was $3.3 million to be recognized over a weighted-average remaining vesting period of approximately 2.4 years. The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate fair value of stock option awards when granted to employees. <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock price </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.36 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 126.3 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.00 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> </table></div>   Risk‑free interest rate—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of our stock options. Dividend yield— We have not paid any dividends on our common stock since inception and do not anticipate paying dividends on our common stock in the foreseeable future. Expected volatility—We base expected volatility on the trading price of our common stock. Expected term—The expected option term represents the period that stock‑based awards are expected to be outstanding based on the simplified method provided in SAB No. 107, which SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at‑the‑money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non‑transferable and non‑hedgeable. In December 2007, the SEC issued SAB No. 110, Share‑Based Payment, (“SAB No. 110”). SAB No. 110 was effective January 1, 2008 and expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC 718. We will use the simplified method until we have the historical data necessary to provide a reasonable estimate of expected life in accordance with SAB No. 107, as amended by SAB No. 110. For the expected term, we have “plain‑vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107. Forfeitures—ASC 718 allows for the election of forfeitures to be estimated at the time of grant and revised if necessary, in subsequent periods if actual forfeitures differ from those estimates. At April 1, 2016, we determined that we had sufficient history of issuing stock options and decreased our estimated forfeiture rate from 10%, which was based on the historical experience of our former parent, to 3%, which is our actual historical forfeiture rate. The forfeiture rate was 10% through the end of the 3rd fiscal quarter ended March 31, 2016 and was the adjusted to 3% through the end of the fiscal year June 30, 2016 based on the aforementioned historical analysis. The forfeiture rate was 3% for the six months ended June 30, 2020 and 2019. We will continue to analyze the forfeiture rate on at least an annual basis or when there are any identified triggers that would justify immediate review. <div /></div> </div>

5436366

5412045

-15.16

-7.48

-1.43

-0.58

<div> <div> Net loss per share   Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. <div /></div> </div>

<div> <div> 10. Loss per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with ASC 260, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. In addition, the net loss attributable to common stockholders’ is adjusted for the preferred stock deemed dividends related accretion of beneficial conversion feature and other discount on this instrument for the periods in which the preferred stock is outstanding. The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Basic and diluted net (loss) income per common share </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Numerator: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,940,080) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,020,898) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (9,166,697) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,004,610) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Preferred stock deemed dividend </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5,412,045) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5,436,366) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss attributable to common stockholders </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,940,080) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (6,432,943) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (9,166,697) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (8,440,976) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Denominator: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average common shares outstanding </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,494,518 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 859,827 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,420,109 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 556,662 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Net loss per share of common stock—basic and diluted </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (0.58) </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (7.48) </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1.43) </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (15.16) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> The following outstanding securities at June 30, 2020 and 2019 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:24.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:24.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common shares issuable upon conversion of Series A preferred stock </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,184 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,184 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common shares issuable upon conversion of Series C preferred stock </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 16,839 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 16,987 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,402,771 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9,010 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants – liability classified </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 107,997 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants – equity classified </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,428,568 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,733,076 </td> </tr> <tr> <td valign="top" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,959,360 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,870,254 </td> </tr> </table></div> The liability and equity classified warrants disclosed above have been excluded from the computation of basic and diluted earnings per share because the exercise price of the warrants exceeds the average market price of our common stock for the period they were outstanding. <div /></div> </div>

346244

381519

P2Y4M24D

3300000

-395528

28775

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.86 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.81 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.31 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.24 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 117 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 69 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.86 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.76 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.26 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.24 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 128 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 75 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.86 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.01 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.50 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.24 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 119 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 65 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.86 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.28 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.78 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.24 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 140 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 72 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 6. Fair Value Measurements The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at June 30, 2020 and December 31, 2019. <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">  Identical Assets </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> and Liabilities </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair value </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> As of June 30, 2020: </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contingent consideration </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,510,000 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,510,000 </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Derivative liabilities related to warrants </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34,398 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34,398 </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> As of December 31, 2019: </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contingent consideration </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Derivative liabilities related to warrants </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> </tr> </table></div>   The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities- warrants in our condensed consolidated statement of operations. See Note 5 for a rollfoward of the derivative liability for the six months ended June 30, 2020 . The financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we  review the assets and liabilities that are subject to ASC 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.   Contingent consideration was recorded for the acquisition of Ciclofilin on June 10, 2016. The contingent consideration represented the acquisition date fair value of potential future payments, to be paid in cash and our stock, upon the achievement of certain milestones and was estimated based on a probability-weighted discounted cash flow model utilizing a discount rate of 6.5% and a stock price of $19.60. We completed the first segment of our Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (Ciclofilin ) and in the fourth quarter of 2018, we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June, 2016, to the Ciclofilin shareholders. As of June 30, 2020, due to the uncertainty in the timing of the clinical development of the associated product candidate, the entire balance is classified as a non-current liability. The following table presents the change in fair value of the contingent consideration for the six months ended June 30, 2020.       <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Acquisition- </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> related </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contingent </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Consideration </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liabilities: </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at December 31, 2019 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Change in fair value recorded in earnings </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at June 30, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,510,000 </td> </tr> </table></div>   <div /></div> </div>

80000

2430000

2510000

-28775

-5623

-34398

<div> <div> Fair Value of Financial Instruments   Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.   ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td></tr></table></div>   To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.   Financial instruments consist of cash and accounts payable, long-term debt, derivative instruments — warrants and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature, except for derivative instruments — warrants and contingent consideration, which were marked to market at the end of each reporting period. See Note 5 for additional information of the fair value of the derivative liabilities. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. See Note 6 for additional information on the fair value of the contingent consideration. <div /></div> </div>

<div> <div> Foreign Exchange   The functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Our reporting currency is the U.S. dollar. The assets and liabilities of Ciclofilin are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was immaterial at June 30, 2020 and December 31, 2019.   Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in other foreign exchange (gain) loss within the consolidated statements of operations. The impact of foreign exchange gains (losses) was immaterial at June 30, 2020 and December 31, 2019.   <div /></div> </div>

2343570

939909

3374680

1825074

1870924

<div> <div> 7. Indefinite-lived Intangible Assets and Goodwill   IPR&D   Our IPR&D asset consisted of the following at:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Indefinite-lived </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intangible Asset </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> CRV431 balance at December 31, 2019 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,190,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value during the six months ended June 30, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> CRV431 balance at June 30, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,190,000 </td> </tr> </table></div>   No impairment losses were recorded on IPR&D during the six months ended June 30, 2020 and 2019.   Goodwill   The table below provides a roll-forward of our goodwill balance:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill balance at December 31, 2019 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,870,924 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Changes during the six months ended June 30, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill balance at June 30, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,870,924 </td> </tr> </table></div>   No impairment losses were recorded to goodwill during the six months ended June 30, 2020 and 2019. <div /></div> </div>

<div> <div> Goodwill and In-Process Research & Development   In accordance with ASC Topic 350, Intangibles — Goodwill and Other (“ASC Topic 350”), goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually, in our fourth quarter, and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired.   In January 2017, the Financial  Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable.   The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. We adopted ASU 2017-04 on January 1, 2020, and the adoption of this standard did not have a material effect on our condensed condolidated financial statements.   Goodwill relates to amounts that arose in connection with the acquisition of Ciclofilin. Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. As a result of the COVID-19 pandemic, we performed a qualitative assessment of goodwill and determined that it was not more likely than not that the fair value of our reporting was less than its carrying value. There was no impairment of goodwill for the six months ended June 30, 2020 and 2019.   IPR&D acquired in a business combination is capitalized as indefinite-lived assets on our condensed consolidated balance sheets at the acquisition-date fair value. Once the project is completed, the carrying value of the IPR&D is reclassified to other intangible assets, net and is amortized over the estimated useful life of the asset. Post-acquisition research and development expenses related to the IPR&D projects are expensed as incurred. The projected discounted cash flow models used to estimate the fair values of our IPR&D assets, acquired in connection with the Ciclofilin acquisition, reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including: (i) probability of successfully completing clinical trials and obtaining regulatory approval; (ii) market size, market growth projections, and market share; (iii) estimates regarding the timing of and the expected costs to advance clinical programs to commercialization; (iv) estimates of future cash flows from potential product sales; and (v) a discount rate. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The use of different inputs and assumptions could increase or decrease our estimated discounted future cash flows, the resulting estimated fair values and the amounts of related impairments, if any.   If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.   As a result of the COVID-19 pandemic, we performed a qualitative assessment of IPR&D and determined that it was not more likely than not that the asset was impaired. There was no impairment of IPR&D for the six months ended June 30, 2020 and 2019. <div /></div> </div>

-3965624

-1981912

-9071126

-4844509

1000000

-961014

95571

30425

<div> <div> Income Taxes   We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.   In April 2019, we transferred state net operating loss tax credits and received approximately $1.0 million in connection with the sale of the state net operating losses to a third party recorded as an income tax benefit in the consolidated statement of operations. We received approval for the sale of net operating losses through participation in the New Jersey Technology Business Tax Certificate Transfer (NOL) Program. We continue to maintain a full valuation allowance for our domestic operations. The current period income tax expense is related to our foreign operations. <div /></div> </div>

-592104

952851

117422

131256

3190000

540088

441801

8953

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 141,670 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 285,201 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 269,751 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 53,902 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2024 and thereafter </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 750,524 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Present value adjustment </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (57,662) </td> </tr> <tr> <td valign="top" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Lease liability at June 30, 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 692,862 </td> </tr> </table></div>   <div /></div> </div>

750524

53902

269751

285201

141670

57662

P5Y

P3Y

4247015

5791554

20432607

24083632

1251889

2603136

0.0098

17683928

11437399

-45334

-9242

-3321963

-7789316

-1983711

-3004610

-1020898

-1020899

-4226617

-9166697

-9200000

-9166697

-4940080

-4900000

-4940080

-8440976

-6432943

-9166697

-4940080

<div> <div> 4. Recent Accounting Pronouncements   In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance will be effective for us in the first quarter of 2021 on a prospective basis, and early adoption is permitted. We are currently evaluating the impact of the new guidance on our condensed consolidated financial statements.   In August of 2018, the FASB issued ASU 2018-13 — Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends disclosure requirements on fair value measurements in Topic 820. This amendment modifies the valuation process of fair value measurements by removing the disclosure requirements for the valuation processes for Level 3 fair value measurements, clarifying the timing of the measurement uncertainty disclosure, and including the changes in unrealized gains and losses for recurring Level 3 fair value measurements in other comprehensive income if held at the end of the reporting period. It also allows the disclosure of other quantitative information in lieu of the weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and should be applied prospectively for the most recent period presented in the initial fiscal year of adoption. We adopted this standard on January 1, 2020 and the impact that this guidance had on our condensed consolidated financial statements was immaterial.   <div /></div> </div>

3617269

1695568

8962351

4775414

-3617269

-1695568

-8962351

-4775414

100000

200000

100000

800000

692862

266696

274604

300000

540751

418258

800000

797913

672801

700000

0.065

P2Y7M17D

58606

1283

127939

128289

1000000

1500000

700000

500000

45334

11436

400000

4666445

1000

1250000

85581

1827

85581

1827

85581

1827

85581

1827

855808

861033

855808

861033

465693

607126

5844530

11248814

11200000

4600000

1250000

176585

15000000

7000000

12000000

2194

2090567

12000

57166

52679

<div> <div> Property, equipment and depreciation   As of June 30, 2020 and December 31, 2019, we had $52,679 and $57,166, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight‑line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the three months ended June 30, 2020 and 2019  was $7,202 and $8,287 respectively, and was $13,729 and $12,928 for the six months ended June 30, 2020 and 2019, respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at June 30, 2020 or December 31, 2019. <div /></div> </div>

P5Y

P3Y

303547

1250000

1273699

755659

5587671

2950340

<div> <div> Research and Development   Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, Research and Development, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.   We do not currently have any commercial biopharmaceutical products and do not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.   Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. At June 30, 2020 and December 31, 2019, we had prepaid research and development costs of $0.4 million and $0.4 million, respectively. <div /></div> </div>

-83182630

-92349327

0.025

<div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Basic and diluted net (loss) income per common share </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Numerator: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,940,080) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,020,898) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (9,166,697) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,004,610) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Preferred stock deemed dividend </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5,412,045) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5,436,366) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss attributable to common stockholders </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,940,080) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (6,432,943) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (9,166,697) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (8,440,976) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Denominator: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average common shares outstanding </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,494,518 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 859,827 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,420,109 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 556,662 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Net loss per share of common stock—basic and diluted </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (0.58) </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (7.48) </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1.43) </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (15.16) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">  Identical Assets </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> and Liabilities </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair value </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> As of June 30, 2020: </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contingent consideration </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,510,000 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,510,000 </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Derivative liabilities related to warrants </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34,398 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34,398 </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> As of December 31, 2019: </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contingent consideration </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> </tr> <tr> <td valign="bottom" style="width:42.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Derivative liabilities related to warrants </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 101.28%;"> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted Average </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:15.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Per Share </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Per Share </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Term </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance outstanding, December 31, 2019 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,271 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 194.83 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43,182 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.42 </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,361,500 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.63 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.73 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,647,415 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cancelled </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance outstanding, June 30, 2020 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,402,771 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.76 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,641,645 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.72 </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested awards and those expected to vest at June 30, 2020 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,339,385 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8.04 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,537,890 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9.72 </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:35.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested and exercisable at June 30, 2020 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,530 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 586.70 </td> <td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.27 </td> <td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock price </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.36 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 126.3 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:45.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.00 </td> <td valign="bottom" style="width:06.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> </table></div>   <div /></div> </div>

176585

<div> <div> Segment Information   Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.   <div /></div> </div>

34637

34698

20742

13956

17192

10377

6815

402857

316628

86229

394611

310718

83893

P3Y

P10Y

P6Y

1.263

0.0036

11607

13750

40535

2500000

14530

586.70

P6Y3M7D

1361500

43182

1641645

41271

1402771

194.83

7.76

P8Y5M1D

P9Y8M19D

1537890

1339385

8.04

P9Y8M19D

1.65

<div> <div> Share-based payments   ASC Topic 718 “Compensation—Stock Compensation” (“ASC 718”) requires companies to measure the cost of employee and non-employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. Generally, we issue stock options with only service-based vesting conditions and record the expense for awards using the straight-line method.   The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The estimated expected stock volatility is based on the historical volatility of our own traded stock price. The expected term of stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future.   <div /></div> </div>

3.24

1.63

2452.80

2.73

5.36

2.86

1.65

247013

85581

1974

306748

85581

1928

3453608

85581

1843

3760255

85581

1827

6074122

85581

1827

9025061

85581

1827

<div> <div> 3. Summary of Significant Accounting Policies   Use of Estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.   Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in our Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies.   Cash   As of June 30, 2020 and December 31, 2019, cash was $17.6 million and $13.9 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced losses related to these balances.   Fair Value of Financial Instruments   Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.   ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td></tr></table></div>   To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.   Financial instruments consist of cash and accounts payable, long-term debt, derivative instruments — warrants and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature, except for derivative instruments — warrants and contingent consideration, which were marked to market at the end of each reporting period. See Note 5 for additional information of the fair value of the derivative liabilities. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. See Note 6 for additional information on the fair value of the contingent consideration.   Derivative Financial Instruments    We have issued common stock warrants in connection with the execution of certain equity financings. The fair value of the warrants, which were deemed to be derivative instruments based on certain contingent put features, was recorded as a derivative liability under the provisions of ASC Topic 815 Derivatives and Hedging (“ASC 815”) upon issuance. Subsequently, the liability is adjusted to fair value as of the end of each reporting period and the changes in the fair value of derivative liabilities are recorded in the statements of operations under the caption “Change in fair value of derivative financial instruments—warrants.” See Note 5 for additional information.   The fair value of the warrants, issued in connection with the October 2015, April 2016, and April 2017 common stock offerings were deemed to be derivative instruments due to certain contingent put features, was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The warrants, issued in connection with the July 2018 Rights Offering (See Note 5) are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The fair value of warrants was affected by changes in inputs to the Black-Scholes option pricing model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. This model uses Level 3 inputs, including stock price volatility, in the fair value hierarchy established by ASC 820 Fair Value Measurement. At June 30, 2020 and December 31, 2019, the fair value of all warrants was $34,398 and $5,623, respectively, which are classified as a long-term derivative liability on our condensed consolidated balance sheets.   Property, equipment and depreciation   As of June 30, 2020 and December 31, 2019, we had $52,679 and $57,166, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight‑line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the three months ended June 30, 2020 and 2019  was $7,202 and $8,287 respectively, and was $13,729 and $12,928 for the six months ended June 30, 2020 and 2019, respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at June 30, 2020 or December 31, 2019.   Goodwill and In-Process Research & Development   In accordance with ASC Topic 350, Intangibles — Goodwill and Other (“ASC Topic 350”), goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually, in our fourth quarter, and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired.   In January 2017, the Financial  Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable.   The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. We adopted ASU 2017-04 on January 1, 2020, and the adoption of this standard did not have a material effect on our condensed condolidated financial statements.   Goodwill relates to amounts that arose in connection with the acquisition of Ciclofilin. Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. As a result of the COVID-19 pandemic, we performed a qualitative assessment of goodwill and determined that it was not more likely than not that the fair value of our reporting was less than its carrying value. There was no impairment of goodwill for the six months ended June 30, 2020 and 2019.   IPR&D acquired in a business combination is capitalized as indefinite-lived assets on our condensed consolidated balance sheets at the acquisition-date fair value. Once the project is completed, the carrying value of the IPR&D is reclassified to other intangible assets, net and is amortized over the estimated useful life of the asset. Post-acquisition research and development expenses related to the IPR&D projects are expensed as incurred. The projected discounted cash flow models used to estimate the fair values of our IPR&D assets, acquired in connection with the Ciclofilin acquisition, reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including: (i) probability of successfully completing clinical trials and obtaining regulatory approval; (ii) market size, market growth projections, and market share; (iii) estimates regarding the timing of and the expected costs to advance clinical programs to commercialization; (iv) estimates of future cash flows from potential product sales; and (v) a discount rate. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The use of different inputs and assumptions could increase or decrease our estimated discounted future cash flows, the resulting estimated fair values and the amounts of related impairments, if any.   If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.   As a result of the COVID-19 pandemic, we performed a qualitative assessment of IPR&D and determined that it was not more likely than not that the asset was impaired. There was no impairment of IPR&D for the six months ended June 30, 2020 and 2019.   Income Taxes   We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.   In April 2019, we transferred state net operating loss tax credits and received approximately $1.0 million in connection with the sale of the state net operating losses to a third party recorded as an income tax benefit in the consolidated statement of operations. We received approval for the sale of net operating losses through participation in the New Jersey Technology Business Tax Certificate Transfer (NOL) Program. We continue to maintain a full valuation allowance for our domestic operations. The current period income tax expense is related to our foreign operations.   Contingencies   In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized.   Research and Development   Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, Research and Development, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.   We do not currently have any commercial biopharmaceutical products and do not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.   Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. At June 30, 2020 and December 31, 2019, we had prepaid research and development costs of $0.4 million and $0.4 million, respectively.   Share-based payments   ASC Topic 718 “Compensation—Stock Compensation” (“ASC 718”) requires companies to measure the cost of employee and non-employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. Generally, we issue stock options with only service-based vesting conditions and record the expense for awards using the straight-line method.   The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The estimated expected stock volatility is based on the historical volatility of our own traded stock price. The expected term of stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future.   Foreign Exchange   The functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Our reporting currency is the U.S. dollar. The assets and liabilities of Ciclofilin are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was immaterial at June 30, 2020 and December 31, 2019.   Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in other foreign exchange (gain) loss within the consolidated statements of operations. The impact of foreign exchange gains (losses) was immaterial at June 30, 2020 and December 31, 2019.   Segment Information   Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.   Net loss per share   Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.   <div /></div> </div>

1975051

76652839

-76463932

855808

930311

645047

77328219

-78447643

855808

908632

18029143

95772959

345

-79468542

855808

868573

16185592

97651006

375

-83182630

855808

861033

18767686

104459486

606

-87409247

855808

861033

18292078

108923663

901

-92349327

855808

861033

<div> <div> 5. Stockholders’ Equity and Derivative Liability — Warrants   Series A Convertible Preferred Stock   On October 14, 2014, our Board of Directors authorized the sale and issuance of up to 1,250,000 shares of Series A Convertible Preferred Stock (the “Series A”). All shares of the Series A were issued between October 2014 and February 2015. Each share of the Series A is convertible at the option of the holder into the number of shares of common stock determined by dividing the stated value of such share by the conversion price that is subject to adjustment. As of June 30, 2020, there were 85,581 shares outstanding. During the six months ended June 30, 2020,  no shares of the Series A were converted. Series C Convertible Preferred Stock Issuance   On July 3, 2018, we completed a rights offering pursuant to our effective registration statement on Form S-1. We offered for sale units in the rights offering and each unit sold in connection with the rights offering consists of 1 share of our Series C Convertible Preferred Stock, or Series C, and common stock warrants (the “Rights Offering”). Upon completion of the offering, pursuant to the rights offering, we sold an aggregate of 10,826 units at an offering price of $1,000 per unit comprised of 10,826 shares of Series C and 88,928 common stock warrants. As of June 30, 2020, there were 1,827 shares outstanding. During the six months ended June 30, 2020,  no shares of the Series C were converted.   Common Stock and Warrant Offering   On October 7, 2015, we entered into an underwriting agreement related to the public offering and sale of 8,929 shares of common stock and warrants to purchase up to 5,357 shares of common stock, at a fixed combined price to the public of $1,680 under our prior shelf registration statement on Form S-3. The shares of common stock and warrants were issued separately on October 13, 2015. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $2,380.00 per share. There is not, nor is there expected to be, any trading market for the warrants issued in the offering contemplated by the Underwriting Agreement.   The gross proceeds to us were $15.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $1.5 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $12.8 million.   If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statements of operations. Upon the issuance of these warrants, the fair value of approximately $4.4 million was recorded as derivative financial instruments liability-warrants.   The fair value of these liability classified warrants was estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of June 30, 2020 and December 31, 2019:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.86 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.28 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.78 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.24 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 140 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 72 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   On April 4, 2016, we closed a public offering of 8,803 shares of our common stock and warrants to purchase up to 4,401 shares of common stock, at a fixed combined price to the public of $795.20 under our prior shelf registration statement on Form S-3. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $952.00 per share. The gross proceeds to us were $7.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $0.7 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $4.2 million.   If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the Fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such Fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations. Upon the issuance of these warrants, the fair value of approximately $1.5 million was recorded as derivative financial instruments liability-warrants.   The fair value of these liability classified warrants was estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of June 30, 2020 and December 31, 2019:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.86 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.76 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.26 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.24 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 128 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 75 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   On April 25, 2017, we closed a public offering of 21,429 shares of our common stock and warrants to purchase up to 10,714 shares of common stock, at a fixed combined price to the public of $560.00 under our prior shelf registration statement on Form S-3. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $700.00 per share. The gross proceeds to us were $12.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $0.5 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $7.5 million.   If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have  determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations and comprehensive loss. Upon the issuance of these warrants, the fair value of approximately $4.0 million was recorded as derivative financial instruments liability-warrants.   The fair value of these liability classified warrants were estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement.   The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of June 30, 2020 and December 31, 2019:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.86 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.81 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.31 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.24 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 117 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 69 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The warrants, issued in connection with the July 2018 Rights Offering are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside of our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The fair value of these liability classified warrants were estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement.   The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of June 30, 2020 and December 31, 2019:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.86 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.01 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.50 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.24 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 119 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 65 </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:69.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:04.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The following table sets forth the components of changes in our derivative financial instruments liability balance for the six months ended June 30, 2020: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Derivative </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Instrument </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Date </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Liability </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2019 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance of derivative financial instruments liability </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value of warrants for the six months ended June 30, 2020 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 28,775 </td> </tr> <tr> <td valign="bottom" style="width:16.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:56.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance of derivative financial instruments liability </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34,398 </td> </tr> </table></div>   Common Stock Offering   On February 12, 2020, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc., as agent (“B. Riley FBR”), pursuant to which we may offer and sell, from time to time, through B. Riley FBR, shares of our common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $7,000,000 (the “Shares”). The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-229534) filed by us with the Securities and Exchange Commission (the “SEC”) on February 6, 2019, as amended on February 13, 2019, and declared effective by the SEC on February 19, 2019, as supplemented by a prospectus supplement dated February 12, 2020 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). Also, on March 27, 2020, we filed a prospectus supplement to the Form S-3 (File No. 333-229534) pursuant to which we may offer and sell an additional $4.6 million. As of June 30, 2020, under the Sales Agreement we sold 5,262,806 shares of our common stock resulting in net proceeds of $11.2 million from the “at the market offerings” Pursuant to the Sales Agreement, B. Riley FBR may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made by means of ordinary brokers’ transactions, including on The Nasdaq Capital Market, at market prices or as otherwise agreed with B. Riley FBR. B. Riley FBR will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares from time to time, based upon instructions from us, including any price or size limits or other customary parameters or conditions we may impose. <div /></div> </div>

500428

424

-46

1824473

-85

-521

-10570

1439

8929

8803

21429

10826

47429

1031071

521

10570

2311867

5262806

2950939

46000

-46000

11175820

182

-85000

-521000

-10570002

486283

486278

5844524

5844421

103

11091002

330

3802201

330

312600

6976201

6788465

6788234

231

4460349

4460054

295

74357

89389

<div> <div> Use of Estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.   Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in our Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies. <div /></div> </div>

2.31

1.66

1.26

75.00

1.66

3.50

1.66

0.78

1.66

1.81

117

0.24

0.76

128.00

0.24

3.01

119

0.24

0.28

140

0.24

556662

859827

6420109

8494518

EX-101.SCH 8 hepa-20200630.xsd EX-101.SCH 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Commitments and Contingencies - Future minimum rental payments under the Company's noncancelable operating leases (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Changes in Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Business Overview link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Basis of Presentation and Going Concern link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Indefinite-lived Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Accounting for Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Loss per Share link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Stockholder’s Equity and Derivative Liability - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Indefinite-lived Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Accounting for Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Business Overview (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Basis of Presentation and Going Concern - Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Basis of Presentation and Going Concern - PPP Loan (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies - Cash (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies - Derivative financial instruments (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Summary of Significant Accounting Policies - Property, equipment and depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Summary of Significant Accounting Policies - Goodwill and In-Process Research and Development (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Series A Convertible Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Series C Preferred Stock Issuances and Beneficial Conversion Feature (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Common Stock and Warrant Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Components of changes (Details) link:presentationLink link:calculationLink link:definitionLink 40505 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Common Stock Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Indefinite-lived Intangible Assets and Goodwill - IPR&D (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Indefinite-lived Intangible Assets and Goodwill - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Accounting for Share-Based Payments - Equity Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Accounting for Share-Based Payments - Activity (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Accounting for Share-Based Payments - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Commitments and Contingencies - Contractual Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Commitments and Contingencies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants link:presentationLink link:calculationLink link:definitionLink 40306 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details) link:presentationLink link:calculationLink link:definitionLink 40307 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 hepa-20200630_cal.xml EX-101.CAL EX-101.DEF 10 hepa-20200630_def.xml EX-101.DEF EX-101.LAB 11 hepa-20200630_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement Statement Changes in Stockholders' Equity Document Type Document Period End Date Entity Registrant Name Entity Current Reporting Status Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Entity Interactive Data Current Condensed Consolidated Balance Sheets Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock [Member] Series A Series C Preferred Stock [Member] Series C Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash Cash Prepaid Expense, Current Prepaid expenses Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset ROU assets Right-of-use assets Indefinite-Lived Intangible Assets (Excluding Goodwill) In-process research and development, ending balance In-process research and development, beginning balance In-process research and development Goodwill Ending balance Beginning balance Goodwill Other Assets Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders’ Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total accrued expenses Operating Lease, Liability, Current Operating lease liabilities, current Current lease liabilities Liabilities, Current Total current liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Contingent consideration Secured Long-term Debt, Noncurrent Long-term debt Deferred Income Tax Liabilities, Net Deferred tax liability Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Non-current lease liabilities Derivative Liability, Noncurrent Derivative financial instruments, at estimated fair value-warrants Derivative financial instruments, at estimated fair value—warrants Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 11) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Convertible preferred stock Common Stock, Value, Issued Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 9,025,061 and 3,760,255 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively. Additional Paid in Capital, Common Stock Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Convertible preferred stock, par value Preferred Stock, Shares Authorized Convertible preferred stock, shares authorized Preferred stock issued (in shares) Convertible preferred stock, shares issued Preferred shares issued (in shares) Preferred Stock, Shares Outstanding Convertible preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations and Comprehensive Loss Costs and Expenses [Abstract] Costs and expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Amount of expense (income) related to adjustment to fair value of debt. Fair Value Adjustment Of Debt Change in fair value of debt Interest Expense, Debt Interest on debt Amount of expense (income) related to adjustment to fair value of warrant liability and contingent consideration. Fair Value Adjustment Of Warrants and Contingent consideration Change in fair value of derivative instruments-warrants and contingent consideration Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Income tax (expense) benefit Net Income (Loss) Attributable to Parent Net loss Net loss Dividends, Preferred Stock Deemed dividend (see Note 5) Preferred stock deemed dividend Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common shareholders Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted Weighted average common shares outstanding (in shares) Earnings Per Share, Basic and Diluted [Abstract] Net loss per common share: (see Note 10) Earnings Per Share, Basic and Diluted Basic and diluted Net loss per share of common stock-basic and diluted (in dollars per share) Condensed Consolidated Statements of Changes in Stockholders’ Equity Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Preferred Stock [Member] Preferred Stock Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid in Capital Retained Earnings [Member] Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Changes in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock based compensation expense Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of preferred stock to common Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of preferred stock to common (in shares) Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs Offering costs Placement Agent Warrants Issued Placement agent warrants Amount of a favorable spread to a preferred stock holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date. Preferred Stock, Convertible, Beneficial Conversion Feature Beneficial conversion feature of preferred stock The amount of accretion of beneficial conversion feature of preferred stock. Accretion of Beneficial Conversion Feature Accretion of beneficial conversion feature Accretion of discount. Adjustments to Additional Paid in Capital, Discount Accretion Accretion of discount Stock Issued During Period, Value, New Issues Issuance of stock, net Stock Issued During Period, Shares, New Issues Issuance of stock, net (in shares) Value of warrants issued as a result of the exercise of warrants. Stock Issued During Period Value Warrants Exercised Warrant exercises Number of warrants exercised during the current period. Stock Issued During Period Shares Warrants Exercised Change in fair value of warrant liability related to warrant exercise (in shares) Warrant exercises (in shares) Debt redemption fair value Issuance of common stock, debt redemption Debt Conversion, Converted Instrument, Shares Issued Issuance of common stock, debt redemption (in shares) Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation expense Stock-based compensation Depreciation, Depletion and Amortization Depreciation and amortization Fair Value Adjustment of Warrants Change in fair value of derivative instrument-warrants Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Change in fair value of contingent consideration Amount of increase or decrease in the fair value of debt. Change In Fair Value Of Debt Change in fair value of debt Increase (decrease) in noncash interest expense. Non Cash Interest Expense Non-cash interest expense Amortization of Debt Discount (Premium) Amortization of debt discount recorded as interest expense Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability Deferred tax liability adjustment Change in deferred tax liability Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from disposal of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from the issuance of common stock, net of issuance costs Proceeds from issuance of stock Represents information pertaining to proceeds from issuance of convertible preferred stock and warrants. Proceeds from Issuance of Convertible Preferred Stock and Warrants Proceeds from issuance of preferred stock and warrants Proceeds from Warrant Exercises Proceeds from the exercise of warrants Proceeds from Issuance of Debt Proceeds from debt financing Repayments of Debt Repayment of debt financing Repayments of Convertible Debt Repayment of convertible debt Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash at end of period Cash at beginning of period Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplementary disclosure of cash flow information: Interest Paid Cash paid for interest Supplemental Cash Flow Information [Abstract] Supplementary disclosure of non-cash financing activities: Conversion of Stock, Amount Converted Conversion of preferred stock Preferred Stock, Accretion of Conversion Discount Accretion of Series C preferred stock discount upon conversion Preferred Stock, Beneficial Conversion Feature Beneficial conversion factor of preferred stock accreted as deemed dividend Stock Issued Fair value of shares issued Issuance of common stock for debt redemption The amount effected in non-cash financing activities due to adoption of lease accounting. Adoption of Lease Accounting, Non-Cash Financing Activities Adoption of lease accounting Represents warrants issued to placement agent. Warrants issued to placement agent Warrants issued to placement agent No definition available. Business Overview The entire disclosure for Business Overview Footnote. Business Overview Text Block Business Overview Basis of Presentation and Going Concern The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Also includes the entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. Basis Of Presentation And Substantial Doubt about Going Concern [Text Block] Basis of Presentation and Going Concern Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Recent Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Recent Accounting Pronouncements No definition available. Stockholders' Equity and Derivative Liability - Warrants Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity and Derivative Liability - Warrants Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Indefinite-lived Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Indefinite-lived Intangible Assets and Goodwill Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities Accounting for Share-Based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Accounting for Share-Based Payments Loss per Share Earnings Per Share [Text Block] Loss per Share Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Derivatives, Policy [Policy Text Block] Derivative Financial Instruments Property, Plant and Equipment, Policy [Policy Text Block] Property, equipment and depreciation Goodwill and Intangible Assets, Policy [Policy Text Block] Goodwill and In-Process Research & Development Income Tax, Policy [Policy Text Block] Income Taxes Commitments and Contingencies, Policy [Policy Text Block] Contingencies Research and Development Expense, Policy [Policy Text Block] Research and Development Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based payments Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Exchange Segment Reporting, Policy [Policy Text Block] Segment Information Earnings Per Share, Policy [Policy Text Block] Net loss per share Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Represents the Warrants issued on October 13th, 2015. October132015 [Member] October 13 2015 Represents the Warrants issued on April 4th, 2016. April42016 [Member] April 4 2016 Represents the Warrants issued on April 25th 2017. April252017 [Member] April 25 2017 Represents the warrants issued on July 3rd 2018 July3rd2018 [Member] July 3 2018 Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Schedule of assumptions used to measure the warrants to remeasure liability Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. Also includes tabular disclosure of reconciliation of beginning and ending balances of financial instrument. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, and Financial Instrument Reconciliation [Table Text Block] Schedule of changes in derivative financial instruments liability balance Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of liabilities measured and recognized at fair value on a recurring basis Represents tabular information of changes in fair value of contingent consideration. Schedule Of Fair Value For Contingent Consideration Table Text Block Schedule of changes in fair value of contingent consideration Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of IPR&D asset Schedule of Goodwill [Table Text Block] Schedule of roll-forward of goodwill balance Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued liabilities Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock based compensation expense EX-101.PRE 12 hepa-20200630_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 05, 2020
Document and Entity Information
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Entity Registrant Name	HEPION PHARMACEUTICALS, INC.
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		9,025,153
Entity Central Index Key	0001583771
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Interactive Data Current	Yes

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 17,561,813	$ 13,922,972
Prepaid expenses	607,126	465,693
Total current assets	18,168,939	14,388,665
Property and equipment, net	52,679	57,166
Right-of-use assets	672,801	797,913
In-process research and development	3,190,000	3,190,000
Goodwill	1,870,924	1,870,924
Other assets	128,289	127,939
Total assets	24,083,632	20,432,607
Current liabilities:
Accounts payable	972,362	491,557
Accrued expenses	1,356,170	493,636
Operating lease liabilities, current	274,604	266,696
Total current liabilities	2,603,136	1,251,889
Contingent consideration	2,510,000	2,430,000
Long-term debt	176,585
Deferred tax liability	49,177	18,752
Operating lease liabilities, non-current	418,258	540,751
Derivative financial instruments, at estimated fair value-warrants	34,398	5,623
Total liabilities	5,791,554	4,247,015
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 9,025,061 and 3,760,255 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively.	901	375
Additional paid in capital	108,923,663	97,651,006
Accumulated deficit	(92,349,327)	(83,182,630)
Total stockholders' equity	18,292,078	16,185,592
Total liabilities and stockholders' equity	24,083,632	20,432,607
Series A
Stockholders' equity:
Convertible preferred stock	855,808	855,808
Series C
Stockholders' equity:
Convertible preferred stock	$ 861,033	$ 861,033

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	9,025,061	3,760,255
Common stock, shares outstanding	9,025,061	3,760,255
Series A
Convertible preferred stock, par value	$ 10	$ 10
Convertible preferred stock, shares issued	85,581	85,581
Convertible preferred stock, shares outstanding	85,581	85,581
Series C
Convertible preferred stock, par value	$ 1,000	$ 1,000
Convertible preferred stock, shares issued	1,827	1,827
Convertible preferred stock, shares outstanding	1,827	1,827

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Costs and expenses:
Research and development	$ 2,950,340	$ 755,659	$ 5,587,671	$ 1,273,699
General and administrative	1,825,074	939,909	3,374,680	2,343,570
Total operating expenses	4,775,414	1,695,568	8,962,351	3,617,269
Loss from operations	(4,775,414)	(1,695,568)	(8,962,351)	(3,617,269)
Other income (expense):
Change in fair value of debt		(94,154)		(153,795)
Interest on debt		(441,801)		(540,088)
Change in fair value of derivative instruments-warrants and contingent consideration	(69,095)	249,611	(108,775)	345,528
Loss before income taxes	(4,844,509)	(1,981,912)	(9,071,126)	(3,965,624)
Income tax (expense) benefit	(95,571)	961,014	(95,571)	961,014
Net loss	(4,940,080)	(1,020,898)	(9,166,697)	(3,004,610)
Deemed dividend (see Note 5)		(5,412,045)		(5,436,366)
Net loss attributable to common shareholders	$ (4,940,080)	$ (6,432,943)	$ (9,166,697)	$ (8,440,976)
Weighted average common shares outstanding:
Basic and diluted	8,494,518	859,827	6,420,109	556,662
Net loss per common share: (see Note 10)
Basic and diluted	$ (0.58)	$ (7.48)	$ (1.43)	$ (15.16)

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Preferred Stock Preferred Stock Series D	Preferred Stock Preferred Stock Series E	Preferred Stock Series A	Preferred Stock Series C	Preferred Stock Series D	Preferred Stock Series E	Common Stock Private placement	Common Stock	Additional Paid in Capital Preferred Stock	Additional Paid in Capital Private placement	Additional Paid in Capital	Accumulated Deficit	Preferred Stock	Private placement	Total
Balance at Dec. 31, 2018			$ 855,808	$ 930,311				$ 25			$ 76,652,839	$ (76,463,932)			$ 1,975,051
Balance (in shares) at Dec. 31, 2018			85,581	1,974				247,013
Changes in Stockholders' Equity
Net loss												(1,983,711)			(1,983,711)
Stock based compensation expense											17,506				17,506
Conversion of preferred stock to common				$ (46,000)							46,000
Conversion of preferred stock to common (in shares)				(46)				424
Accretion of discount				$ 24,321							(24,321)
Issuance of stock, net							$ 5			$ 486,278				$ 486,283
Issuance of stock, net (in shares)							47,429
Issuance of common stock, debt redemption								$ 1			149,917				149,918
Issuance of common stock, debt redemption (in shares)								11,882
Balance at Mar. 31, 2019			$ 855,808	$ 908,632				$ 31			77,328,219	(78,447,643)			645,047
Balance (in shares) at Mar. 31, 2019			85,581	1,928				306,748
Balance at Dec. 31, 2018			$ 855,808	$ 930,311				$ 25			76,652,839	(76,463,932)			1,975,051
Balance (in shares) at Dec. 31, 2018			85,581	1,974				247,013
Changes in Stockholders' Equity
Net loss															(3,004,610)
Balance at Jun. 30, 2019			$ 855,808	$ 868,573				$ 345			95,772,959	(79,468,542)			18,029,143
Balance (in shares) at Jun. 30, 2019			85,581	1,843				3,453,608
Balance at Mar. 31, 2019			$ 855,808	$ 908,632				$ 31			77,328,219	(78,447,643)			645,047
Balance (in shares) at Mar. 31, 2019			85,581	1,928				306,748
Changes in Stockholders' Equity
Net loss												(1,020,899)			(1,020,898)
Stock based compensation expense											17,133				17,133
Conversion of preferred stock to common				$ (85,000)	$ (521,000)	$ (10,570,002)		$ 182			11,175,820
Conversion of preferred stock to common (in shares)				(85)	(521)	(10,570)		1,824,473
Offering costs					$ (29,526)	$ (472,311)					(536,787)				(1,038,624)
Placement agent warrants					(48,250)	(244,895)					293,145
Beneficial conversion feature of preferred stock					(186,692)	(581,350)					768,042
Accretion of beneficial conversion feature					186,692	581,350					(768,042)
Accretion of discount				$ 44,941	$ 286,176	$ 4,311,007					(4,642,124)
Issuance of stock, net	$ 312,600	$ 6,976,201						$ 103	$ 3,802,201	$ 330	5,844,421		$ 11,091,002	$ 330	5,844,524
Issuance of stock, net (in shares)	521	10,570						1,031,071
Warrant exercises								$ 25			2,090,542				2,090,567
Warrant exercises (in shares)								248,877
Issuance of common stock, debt redemption								$ 4			400,059				400,063
Issuance of common stock, debt redemption (in shares)								42,439
Balance at Jun. 30, 2019			$ 855,808	$ 868,573				$ 345			95,772,959	(79,468,542)			18,029,143
Balance (in shares) at Jun. 30, 2019			85,581	1,843				3,453,608
Balance at Dec. 31, 2019			$ 855,808	$ 861,033				$ 375			97,651,006	(83,182,630)			16,185,592
Balance (in shares) at Dec. 31, 2019			85,581	1,827				3,760,255
Changes in Stockholders' Equity
Net loss												(4,226,617)			(4,226,617)
Stock based compensation expense											8,246				8,246
Issuance of stock, net								$ 231			6,788,234				6,788,465
Issuance of stock, net (in shares)								2,311,867
Warrant exercises											12,000				12,000
Warrant exercises (in shares)								2,000
Balance at Mar. 31, 2020			$ 855,808	$ 861,033				$ 606			104,459,486	(87,409,247)			18,767,686
Balance (in shares) at Mar. 31, 2020			85,581	1,827				6,074,122
Balance at Dec. 31, 2019			$ 855,808	$ 861,033				$ 375			97,651,006	(83,182,630)			16,185,592
Balance (in shares) at Dec. 31, 2019			85,581	1,827				3,760,255
Changes in Stockholders' Equity
Net loss															(9,166,697)
Balance at Jun. 30, 2020			$ 855,808	$ 861,033				$ 901			108,923,663	(92,349,327)			18,292,078
Balance (in shares) at Jun. 30, 2020			85,581	1,827				9,025,061
Balance at Mar. 31, 2020			$ 855,808	$ 861,033				$ 606			104,459,486	(87,409,247)			18,767,686
Balance (in shares) at Mar. 31, 2020			85,581	1,827				6,074,122
Changes in Stockholders' Equity
Net loss												(4,940,080)			(4,940,080)
Stock based compensation expense											4,123				4,123
Issuance of stock, net								$ 295			4,460,054				4,460,349
Issuance of stock, net (in shares)								2,950,939
Balance at Jun. 30, 2020			$ 855,808	$ 861,033				$ 901			$ 108,923,663	$ (92,349,327)			$ 18,292,078
Balance (in shares) at Jun. 30, 2020			85,581	1,827				9,025,061

XML 18 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (9,166,697)	$ (3,004,610)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	402,857	34,637
Depreciation and amortization	13,729	12,928
Change in fair value of derivative instrument-warrants	28,775	(395,528)
Change in fair value of contingent consideration	80,000	50,000
Change in fair value of debt		153,795
Non-cash interest expense		49,729
Amortization of debt discount recorded as interest expense		486,612
Change in deferred tax liability	30,425
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	952,851	(592,104)
Prepaid expenses and other assets	(131,256)	(117,422)
Net cash used in operating activities	(7,789,316)	(3,321,963)
Cash flows from investing activities:
Purchase of property and equipment	(11,436)	(45,334)
Proceeds from disposal of property and equipment	2,194
Net cash used in investing activities	(9,242)	(45,334)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs	11,248,814	5,844,530
Proceeds from the exercise of warrants	12,000	2,090,567
Proceeds from debt financing	176,585	1,250,000
Repayment of debt financing		(1,250,000)
Repayment of convertible debt		(303,547)
Net cash provided by financing activities	11,437,399	17,683,928
Net increase in cash	3,638,841	14,316,631
Cash at beginning of period	13,922,972	2,832,429
Cash at end of period	$ 17,561,813	17,149,060
Supplementary disclosure of cash flow information:
Cash paid for interest		8,953
Supplementary disclosure of non-cash financing activities:
Accretion of Series C preferred stock discount upon conversion		4,666,445
Beneficial conversion factor of preferred stock accreted as deemed dividend		768,042
Issuance of common stock for debt redemption		500,428
Adoption of lease accounting		692,918
Warrants issued to placement agent		293,145
Series C
Supplementary disclosure of non-cash financing activities:
Conversion of preferred stock		131,000
Series D
Cash flows from financing activities:
Proceeds from issuance of preferred stock and warrants		403,120
Supplementary disclosure of non-cash financing activities:
Conversion of preferred stock		521,000
Series E
Cash flows from financing activities:
Proceeds from issuance of preferred stock and warrants		9,649,258
Supplementary disclosure of non-cash financing activities:
Conversion of preferred stock		$ 10,570,002

XML 19 R7.htm IDEA: XBRL DOCUMENT

Business Overview	6 Months Ended
Business Overview	Jun. 30, 2020
Business Overview
Business Overview	1. Business Overview Hepion Pharmaceuticals, Inc. (we, our, or us) is a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. On July 18, 2019, we filed a certificate of amendment (the “Certificate of Amendment”) to our certificate of incorporation (the “Certificate”) to change our name from “ContraVir Pharmaceuticals, Inc.” to “Hepion Pharmaceuticals, Inc.” The name change became effective as of July 18, 2019. We are developing CRV431 as our lead molecule. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. To date, in vitro and/or in vivo studies have demonstrated reductions in HBV DNA, HBsAg, HBeAg, inhibition of virus uptake (NTCP transport inhibition), and stimulation of innate immunity. Importantly, in vivo studies in a NASH model of fibrosis and HCC have repeatedly demonstrated CRV431 reduces fibrosis scores and overall liver tumor burden. Hence, CRV431 is a pleiotropic molecule that may not only treat liver disease but may also serve to reduce important risk factors (e.g., HBV) for developing the disease. We have completed a phase 1 study with CRV431 demonstrating safety, tolerability, and pharmacokinetics (PK). CRV431 On May 10, 2018, we submitted an Investigational New Drug Application (“IND”) to the U.S. Food and Drug Administration (“FDA”) to support initiation of our CRV431 HBV clinical development program in the United States and received approval in June 2018. We completed the first segment of Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (“Ciclofilin”) and we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June 2016, to the Ciclofilin shareholders. On June 17, 2019, we submitted an IND to the FDA to support initiation of our CRV431 NASH clinical development program in the United States and received approval in July 2019.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Going Concern	6 Months Ended
Basis of Presentation and Going Concern	Jun. 30, 2020
Basis of Presentation and Going Concern
Basis of Presentation and Going Concern	2. Basis of Presentation and Going Concern These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2019 was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 contained in our Annual Report on Form 10-K. Principles of Consolidation The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation. Going Concern As of June 30, 2020, we had $17.6 million in cash, we had an accumulated deficit of $92.3 million, and we had working capital of $15.6 million. For the six months ended June 30, 2020 cash used in operating activities was $7.8 million and for the three and six months ended June 30, 2020 we had a net loss of $4.9 million and $9.2 million, respectively. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through issuances of convertible debt, common stock and preferred stock. We expect to continue to incur losses for the next several years as we expand our research, development and clinical trials of CRV431. We are unable to predict the extent of any future losses or when we will become profitable, if at all. These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. These condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms. COVID-19 Pandemic On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation and its impact on our financial condition, liquidity, operations, suppliers, industry, and workforce. While we have not experienced delays to date, we may experience delays in the conduct of clinical testing of our product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. The COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidate. The evolving COVID-19 pandemic is also likely to directly or indirectly impact the pace of enrollment in our CRV431 clinical trials for at least the next several months and possibly longer as patients may avoid or may not be able to travel to healthcare facilities and physicians' offices unless due to a health emergency. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial, related to the COVID-19 pandemic, or in obtaining sufficient supplies of clinical trial materials. Any delays in completing our clinical trials will increase our costs, slow down our product development, timeliness and approval process and delay our ability to generate revenue. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change and we do not yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. Although we cannot estimate the length or gravity of the impact of the COVID-19 outbreak nor estimate the potential impact to our fiscal year 2020 financial statements at this time, if the pandemic continues, it could have a material adverse effect on our results of future operations, financial position, liquidity, and capital resources, and those of the third parties on which we rely in fiscal year 2020. On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), as amended on June 5, 2020 by the Paycheck Protection Program (“PPP”). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. On April 13, 2020, we were granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggregate amount of $176,585, pursuant to the PPP under Division A, Title I of the CARES Act. We are continuing to evaluate and examine the impacts the CARES Act may have on our business, results of operations, financial condition or liquidity. The Loan, which was in the form of a Note dated April 13, 2020 issued by us, matures on April 13, 2022 and bears interest at a rate of 0.98% per annum, payable monthly commencing on November 13, 2020. The Note may be prepaid by us at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, rent and utilities. We intend to use the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. We have a good-faith belief that we properly satisfied all eligibility requirements for the PPP loan and we intend to comply with the loan forgiveness provisions in the legislation; however, there can be no assurance that we will obtain full forgiveness of the loan based on the legislation. The PPP Loan is reflected in the condensed consolidated balance sheet as long-term debt based upon the terms and conditions of the Loan agreement.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Use of Estimates

Cash

Fair Value of Financial Instruments

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.

Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Derivative Financial Instruments

The warrants, issued in connection with the July 2018 Rights Offering (See Note 5) are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.

Property, equipment and depreciation

As of June 30, 2020 and December 31, 2019, we had $52,679 and $57,166, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight‑line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the three months ended June 30, 2020 and 2019 was $7,202 and $8,287 respectively, and was $13,729 and $12,928 for the six months ended June 30, 2020 and 2019, respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at June 30, 2020 or December 31, 2019.

Goodwill and In-Process Research & Development

In accordance with ASC Topic 350, Intangibles — Goodwill and Other (“ASC Topic 350”), goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually, in our fourth quarter, and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired.

Income Taxes

Contingencies

Research and Development

Share-based payments

Foreign Exchange

Segment Information

Net loss per share

XML 22 R10.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements	6 Months Ended
Recent Accounting Pronouncements	Jun. 30, 2020
Recent Accounting Pronouncements
Recent Accounting Pronouncements	4. Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance will be effective for us in the first quarter of 2021 on a prospective basis, and early adoption is permitted. We are currently evaluating the impact of the new guidance on our condensed consolidated financial statements. In August of 2018, the FASB issued ASU 2018-13 — Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends disclosure requirements on fair value measurements in Topic 820. This amendment modifies the valuation process of fair value measurements by removing the disclosure requirements for the valuation processes for Level 3 fair value measurements, clarifying the timing of the measurement uncertainty disclosure, and including the changes in unrealized gains and losses for recurring Level 3 fair value measurements in other comprehensive income if held at the end of the reporting period. It also allows the disclosure of other quantitative information in lieu of the weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and should be applied prospectively for the most recent period presented in the initial fiscal year of adoption. We adopted this standard on January 1, 2020 and the impact that this guidance had on our condensed consolidated financial statements was immaterial.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants

6 Months Ended

Jun. 30, 2020

Stockholders' Equity and Derivative Liability - Warrants

Stockholders' Equity and Derivative Liability - Warrants

5. Stockholders’ Equity and Derivative Liability — Warrants

Series A Convertible Preferred Stock

Series C Convertible Preferred Stock Issuance

Common Stock and Warrant Offering


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		0.28	years		0.78	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		140	%		72	%
Dividend yield		—			—

If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the Fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such Fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations. Upon the issuance of these warrants, the fair value of approximately $1.5 million was recorded as derivative financial instruments liability-warrants.


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		0.76	years		1.26	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		128	%		75	%
Dividend yield		—			—

If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations and comprehensive loss. Upon the issuance of these warrants, the fair value of approximately $4.0 million was recorded as derivative financial instruments liability-warrants.

The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of June 30, 2020 and December 31, 2019:


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		1.81	years		2.31	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		117	%		69	%
Dividend yield		—			—

The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of June 30, 2020 and December 31, 2019:


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		3.01	years		3.50	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		119	%		65	%
Dividend yield		—			—

The following table sets forth the components of changes in our derivative financial instruments liability balance for the six months ended June 30, 2020:


		Number of		Derivative
		Warrants		Instrument
Date	Description	Outstanding		Liability
December 31, 2019	Balance of derivative financial instruments liability		107,998	$	5,623
	Change in fair value of warrants for the six months ended June 30, 2020		—		28,775
June 30, 2020	Balance of derivative financial instruments liability		107,998	$	34,398

Common Stock Offering

As of June 30, 2020, under the Sales Agreement we sold 5,262,806 shares of our common stock resulting in net proceeds of $11.2 million from the “at the market offerings”

XML 24 R12.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2020

Fair Value Measurements

Fair Value Measurements

6. Fair Value Measurements


			Quoted Prices in		Significant
			Active Markets for		Other		Significant
			Identical Assets		Observable		Unobservable
			and Liabilities		Inputs		Inputs
Description	Fair value		(Level 1)		(Level 2)		(Level 3)
As of June 30, 2020:
Contingent consideration	$	2,510,000	$	—	$	—	$	2,510,000
Derivative liabilities related to warrants	$	34,398	$	—	$	—	$	34,398

As of December 31, 2019:
Contingent consideration	$	2,430,000	$	—	$	—	$	2,430,000
Derivative liabilities related to warrants	$	5,623	$	—	$	—	$	5,623


	Acquisition-
	related
	Contingent
	Consideration
Liabilities:
Balance at December 31, 2019	$	2,430,000
Change in fair value recorded in earnings		80,000
Balance at June 30, 2020	$	2,510,000

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

Indefinite-lived Intangible Assets and Goodwill

6 Months Ended

Jun. 30, 2020

Indefinite-lived Intangible Assets and Goodwill

Indefinite-lived Intangible Assets and Goodwill

7. Indefinite-lived Intangible Assets and Goodwill

IPR&D

Our IPR&D asset consisted of the following at:


	Indefinite-lived
	Intangible Asset
CRV431 balance at December 31, 2019	$	3,190,000
Change in fair value during the six months ended June 30, 2020		—
CRV431 balance at June 30, 2020	$	3,190,000

No impairment losses were recorded on IPR&D during the six months ended June 30, 2020 and 2019.

Goodwill

The table below provides a roll-forward of our goodwill balance:


	Amount
Goodwill balance at December 31, 2019	$	1,870,924
Changes during the six months ended June 30, 2020		—
Goodwill balance at June 30, 2020	$	1,870,924

No impairment losses were recorded to goodwill during the six months ended June 30, 2020 and 2019.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

6 Months Ended

Jun. 30, 2020

Accrued Liabilities

Accrued Liabilities

8. Accrued Liabilities

Accrued expenses consisted of the following:


	June 30,		December 31,
	2020		2019
Payroll and related costs	$	381,519	$	346,244
Stock-based compensation		390,488		—
Research and development		493,491		12,075
Legal fees		—		2,354
Accrued taxes		89,389		74,357
Other		1,283		58,606
Total accrued expenses	$	1,356,170	$	493,636

XML 27 R15.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments

6 Months Ended

Jun. 30, 2020

Accounting for Share-Based Payments

Accounting for Share-Based Payments

9. Accounting for Share‑Based Payments

On June 3, 2013, we adopted the 2013 Equity Incentive Plan (the “Plan”). Stock options granted under the Plan typically will vest after three years of continuous service from the grant date and will have a contractual term of ten years. Stockholder and Board approval was obtained on December 2, 2014 to increase the number of authorized shares to 11,607 and on December 14, 2016, Stockholder and Board approval was obtained to increase the number of authorized shares to 13,750. Stockholder and Board approval was obtained on February 21, 2018 to increase the number of authorized shares to 40,535. We granted certain stock option awards during the three months ended June 30, 2020 and at the time that these grants were made, we had 0 shares of common stock available for grant under the Plan. We accounted for the option grants as liability-classified awards requiring us to measure the fair value of the awards each reporting period. The liability related to the awards granted in the three months ended June 30, 2020 in the amount of $0.4 million has been included in accrued expenses in our condensed consolidated balance sheet with the corresponding expense included in our condensed consolidated statements of operations and comprehensive loss. At our annual meeting of stockholders on July 30, 2020, we received shareholder approval to increase the number of shares issuable under the Plan to 2,500,000 from 40,535.


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
General and administrative	$	310,718	$	10,377	$	316,628	$	20,742
Research and development		83,893		6,815		86,229		13,956
Total stock-based compensation expense	$	394,611	$	17,192	$	402,857	$	34,698

A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below:


							Weighted
							Average				Weighted Average
	Number of	Exercise Price					Exercise Price		Intrinsic		Remaining
	Options	Per Share					Per Share		Value		Contractual Term
Balance outstanding, December 31, 2019	41,271	$	3.24	-	$	2,452.80	$	194.83	$	43,182	8.42	years
Granted	1,361,500		1.63	-		2.73		1.65		1,647,415
Forfeited	—		—			—		—		—
Cancelled	—		—	-		—		—		—
Balance outstanding, June 30, 2020	1,402,771		3.24	-		2,452.80		7.76		1,641,645	9.72	years
Vested awards and those expected to vest at June 30, 2020	1,339,385		3.24	-		2,452.80		8.04		1,537,890	9.72	years
Vested and exercisable at June 30, 2020	14,530		3.24	-		2,452.80		586.70		—	6.27	years

There were no options granted to employees during the six months ended June 30, 2019. The total fair value of the shares vested during the six months ended June 30, 2019 was de minimis.

The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate fair value of stock option awards when granted to employees.


	Six Months Ended			Six Months Ended
	June 30, 2020			June 30, 2019
Stock price	$	1.65		$	—
Risk-free interest rate		0.36	%		—	%
Dividend yield		—			—
Expected volatility		126.3	%		—	%
Expected term (in years)		6.00	years		—	years

Risk‑free interest rate—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of our stock options.

Dividend yield— We have not paid any dividends on our common stock since inception and do not anticipate paying dividends on our common stock in the foreseeable future.

Expected volatility—We base expected volatility on the trading price of our common stock.

Expected term—The expected option term represents the period that stock‑based awards are expected to be outstanding based on the simplified method provided in SAB No. 107, which SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at‑the‑money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non‑transferable and non‑hedgeable.

In December 2007, the SEC issued SAB No. 110, Share‑Based Payment, (“SAB No. 110”). SAB No. 110 was effective January 1, 2008 and expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC 718. We will use the simplified method until we have the historical data necessary to provide a reasonable estimate of expected life in accordance with SAB No. 107, as amended by SAB No. 110. For the expected term, we have “plain‑vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107.

Forfeitures—ASC 718 allows for the election of forfeitures to be estimated at the time of grant and revised if necessary, in subsequent periods if actual forfeitures differ from those estimates. At April 1, 2016, we determined that we had sufficient history of issuing stock options and decreased our estimated forfeiture rate from 10%, which was based on the historical experience of our former parent, to 3%, which is our actual historical forfeiture rate. The forfeiture rate was 10% through the end of the 3rd fiscal quarter ended March 31, 2016 and was the adjusted to 3% through the end of the fiscal year June 30, 2016 based on the aforementioned historical analysis. The forfeiture rate was 3% for the six months ended June 30, 2020 and 2019. We will continue to analyze the forfeiture rate on at least an annual basis or when there are any identified triggers that would justify immediate review.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Loss per Share

6 Months Ended

Jun. 30, 2020

Loss per Share

Loss per Share

10. Loss per Share

The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:



	Three Months Ended				Six Months Ended
	June 30,				June 30,
Basic and diluted net (loss) income per common share	2020		2019		2020		2019
Numerator:
Net loss	$	(4,940,080)	$	(1,020,898)	$	(9,166,697)	$	(3,004,610)
Preferred stock deemed dividend		—		(5,412,045)		—		(5,436,366)
Net loss attributable to common stockholders	$	(4,940,080)	$	(6,432,943)	$	(9,166,697)	$	(8,440,976)
Denominator:
Weighted average common shares outstanding		8,494,518		859,827		6,420,109		556,662
Net loss per share of common stock—basic and diluted	$	(0.58)	$	(7.48)	$	(1.43)	$	(15.16)

The following outstanding securities at June 30, 2020 and 2019 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:


	Six Months Ended
	June 30,
	2020	2019
Common shares issuable upon conversion of Series A preferred stock	3,184	3,184
Common shares issuable upon conversion of Series C preferred stock	16,839	16,987
Stock options	1,402,771	9,010
Warrants – liability classified	107,998	107,997
Warrants – equity classified	2,428,568	2,733,076
Total	3,959,360	2,870,254

XML 29 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies

Commitments and Contingencies

11. Commitments and Contingencies

Contractual Obligations

Legal Proceedings

Leases

We account for leases in accordance with ASC Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property or equipment for a period in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property and equipment), and (2) the customer has the right to control the use of the identified asset.

We adopted ASC 842 in the first quarter of 2019 using an alternative modified retrospective approach, in which prior periods will not be restated. As a result of the adoption, as of January 1, 2019, we recognized an operating lease liability of $0.8 million based on the present value of the minimum rental payments of the leases and a corresponding ROU asset of $0.8 million. As of June 30, 2020, the ROU assets are $0.7 million, the current lease liabilities are $0.3 million, and the non-current lease liabilities are $0.5 million. The discount rate used to account for our operating leases under ASC 842 is our estimated incremental borrowing rate of 6.5%.


2020	$	141,670
2021		285,201
2022		269,751
2023		53,902
2024 and thereafter		—
Total		750,524
Present value adjustment		(57,662)
Lease liability at June 30, 2020	$	692,862

Employment Agreements

XML 30 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Summary of Significant Accounting Policies

Use of Estimates

Cash

Fair Value of Financial Instruments

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.

Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Derivative Financial Instruments

Property, equipment and depreciation

As of June 30, 2020 and December 31, 2019, we had $52,679 and $57,166, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight‑line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the three months ended June 30, 2020 and 2019 was $7,202 and $8,287 respectively, and was $13,729 and $12,928 for the six months ended June 30, 2020 and 2019, respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at June 30, 2020 or December 31, 2019.

Goodwill and In-Process Research & Development

Income Taxes

Contingencies

Research and Development

XML 31 R19.htm IDEA: XBRL DOCUMENT

Stockholder’s Equity and Derivative Liability - Warrants (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of changes in derivative financial instruments liability balance


		Number of		Derivative
		Warrants		Instrument
Date	Description	Outstanding		Liability
December 31, 2019	Balance of derivative financial instruments liability		107,998	$	5,623
	Change in fair value of warrants for the six months ended June 30, 2020		—		28,775
June 30, 2020	Balance of derivative financial instruments liability		107,998	$	34,398

October 13 2015

Schedule of assumptions used to measure the warrants to remeasure liability


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		0.28	years		0.78	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		140	%		72	%
Dividend yield		—			—

April 4 2016

Schedule of assumptions used to measure the warrants to remeasure liability


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		0.76	years		1.26	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		128	%		75	%
Dividend yield		—			—

April 25 2017

Schedule of assumptions used to measure the warrants to remeasure liability


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		1.81	years		2.31	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		117	%		69	%
Dividend yield		—			—

July 3 2018

Schedule of assumptions used to measure the warrants to remeasure liability


	June 30,			December 31,
	2020			2019
Price of Hepion common stock	$	2.86		$	5.36
Expected warrant term (years)		3.01	years		3.50	years
Risk-free interest rate		0.24	%		1.66	%
Expected volatility		119	%		65	%
Dividend yield		—			—

XML 32 R20.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Measurements

Schedule of liabilities measured and recognized at fair value on a recurring basis


			Quoted Prices in		Significant
			Active Markets for		Other		Significant
			Identical Assets		Observable		Unobservable
			and Liabilities		Inputs		Inputs
Description	Fair value		(Level 1)		(Level 2)		(Level 3)
As of June 30, 2020:
Contingent consideration	$	2,510,000	$	—	$	—	$	2,510,000
Derivative liabilities related to warrants	$	34,398	$	—	$	—	$	34,398

As of December 31, 2019:
Contingent consideration	$	2,430,000	$	—	$	—	$	2,430,000
Derivative liabilities related to warrants	$	5,623	$	—	$	—	$	5,623

Schedule of changes in fair value of contingent consideration

The following table presents the change in fair value of the contingent consideration for the six months ended June 30, 2020.


	Acquisition-
	related
	Contingent
	Consideration
Liabilities:
Balance at December 31, 2019	$	2,430,000
Change in fair value recorded in earnings		80,000
Balance at June 30, 2020	$	2,510,000

XML 33 R21.htm IDEA: XBRL DOCUMENT

Indefinite-lived Intangible Assets and Goodwill (Tables)

6 Months Ended

Jun. 30, 2020

Indefinite-lived Intangible Assets and Goodwill

Schedule of IPR&D asset


	Indefinite-lived
	Intangible Asset
CRV431 balance at December 31, 2019	$	3,190,000
Change in fair value during the six months ended June 30, 2020		—
CRV431 balance at June 30, 2020	$	3,190,000

Schedule of roll-forward of goodwill balance


	Amount
Goodwill balance at December 31, 2019	$	1,870,924
Changes during the six months ended June 30, 2020		—
Goodwill balance at June 30, 2020	$	1,870,924

XML 34 R22.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2020

Accrued Liabilities

Schedule of accrued liabilities


	June 30,		December 31,
	2020		2019
Payroll and related costs	$	381,519	$	346,244
Stock-based compensation		390,488		—
Research and development		493,491		12,075
Legal fees		—		2,354
Accrued taxes		89,389		74,357
Other		1,283		58,606
Total accrued expenses	$	1,356,170	$	493,636

XML 35 R23.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments (Tables)

6 Months Ended

Jun. 30, 2020

Accounting for Share-Based Payments

Schedule of stock based compensation expense


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
General and administrative	$	310,718	$	10,377	$	316,628	$	20,742
Research and development		83,893		6,815		86,229		13,956
Total stock-based compensation expense	$	394,611	$	17,192	$	402,857	$	34,698

Summary of stock option activity and of changes in stock options outstanding under the Plan


							Weighted
							Average				Weighted Average
	Number of	Exercise Price					Exercise Price		Intrinsic		Remaining
	Options	Per Share					Per Share		Value		Contractual Term
Balance outstanding, December 31, 2019	41,271	$	3.24	-	$	2,452.80	$	194.83	$	43,182	8.42	years
Granted	1,361,500		1.63	-		2.73		1.65		1,647,415
Forfeited	—		—			—		—		—
Cancelled	—		—	-		—		—		—
Balance outstanding, June 30, 2020	1,402,771		3.24	-		2,452.80		7.76		1,641,645	9.72	years
Vested awards and those expected to vest at June 30, 2020	1,339,385		3.24	-		2,452.80		8.04		1,537,890	9.72	years
Vested and exercisable at June 30, 2020	14,530		3.24	-		2,452.80		586.70		—	6.27	years

Schedule of weighted-average assumptions used to estimate fair value of stock option awards granted to employees


	Six Months Ended			Six Months Ended
	June 30, 2020			June 30, 2019
Stock price	$	1.65		$	—
Risk-free interest rate		0.36	%		—	%
Dividend yield		—			—
Expected volatility		126.3	%		—	%
Expected term (in years)		6.00	years		—	years

XML 36 R24.htm IDEA: XBRL DOCUMENT

Loss per Share (Tables)

6 Months Ended

Jun. 30, 2020

Loss per Share

Schedule of computation of basic and diluted net loss per share



	Three Months Ended				Six Months Ended
	June 30,				June 30,
Basic and diluted net (loss) income per common share	2020		2019		2020		2019
Numerator:
Net loss	$	(4,940,080)	$	(1,020,898)	$	(9,166,697)	$	(3,004,610)
Preferred stock deemed dividend		—		(5,412,045)		—		(5,436,366)
Net loss attributable to common stockholders	$	(4,940,080)	$	(6,432,943)	$	(9,166,697)	$	(8,440,976)
Denominator:
Weighted average common shares outstanding		8,494,518		859,827		6,420,109		556,662
Net loss per share of common stock—basic and diluted	$	(0.58)	$	(7.48)	$	(1.43)	$	(15.16)

Schedule of outstanding securities excluded from the computation of diluted weighted shares outstanding


	Six Months Ended
	June 30,
	2020	2019
Common shares issuable upon conversion of Series A preferred stock	3,184	3,184
Common shares issuable upon conversion of Series C preferred stock	16,839	16,987
Stock options	1,402,771	9,010
Warrants – liability classified	107,998	107,997
Warrants – equity classified	2,428,568	2,733,076
Total	3,959,360	2,870,254

XML 37 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies

Schedule of future minimum rental payments under the Company's noncancelable operating leases


2020	$	141,670
2021		285,201
2022		269,751
2023		53,902
2024 and thereafter		—
Total		750,524
Present value adjustment		(57,662)
Lease liability at June 30, 2020	$	692,862

XML 38 R26.htm IDEA: XBRL DOCUMENT

Business Overview (Details) - USD ($)	1 Months Ended		6 Months Ended
Business Overview (Details) - USD ($)	Oct. 31, 2018	Jun. 30, 2016	Jun. 30, 2019
Business Overview
Fair value of shares issued			$ 500,428
Ciclofilin
Business Overview
First milestone payment	$ 1,000,000
Number of shares issued	1,439
Issuance of common stock in conjunction with milestone payment	$ 55,398
Percentage of issued and outstanding	2.50%	2.50%

XML 39 R27.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Going Concern - Going Concern (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Going Concern
Cash	$ 17,561,813				$ 17,561,813		$ 13,922,972
Net cash used in operating activities					(7,789,316)	$ (3,321,963)
Net loss	(4,940,080)	$ (4,226,617)	$ (1,020,898)	$ (1,983,711)	(9,166,697)	$ (3,004,610)
Accumulated deficit	(92,349,327)				(92,349,327)		$ (83,182,630)
Working capital	$ 15,600,000				$ 15,600,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 40 R28.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Going Concern - PPP Loan (Details) - PPP Loan	Apr. 13, 2020 USD ($)
Debt
Principal amount	$ 176,585
Interest rate (as percent)	0.98%

XML 41 R29.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Cash (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies
Cash	$ 17,561,813	$ 13,922,972

XML 42 R30.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Derivative financial instruments (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Derivative Financial Instruments
Derivative financial instruments, at estimated fair value—warrants	$ 34,398	$ 5,623
Level 3 \| Warrants
Derivative Financial Instruments
Derivative financial instruments, at estimated fair value—warrants	$ 34,398	$ 5,623

XML 43 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Property, equipment and depreciation (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Property, equipment and depreciation
Property and equipment, net	$ 52,679		$ 52,679		$ 57,166
Depreciation and amortization	$ 7,202	$ 8,287	13,729	$ 12,928
Carrying value adjustments			$ 0		$ 0
Minimum
Property, equipment and depreciation
Estimated useful life			3 years
Maximum
Property, equipment and depreciation
Estimated useful life			5 years

XML 44 R32.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Goodwill and In-Process Research and Development (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Summary of Significant Accounting Policies
Impairment on goodwill	$ 0	$ 0
Impairment of IPR&D	$ 0	$ 0

XML 45 R33.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Income Taxes (Details) - USD ($)	1 Months Ended	6 Months Ended
	Apr. 30, 2019	Jun. 30, 2020
Income Taxes
Deferred tax liability adjustment		$ 30,425
Net operating loss tax credits	$ 1,000,000

XML 46 R34.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Research and Development (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Research and Development
Prepaid research and development costs	$ 0.4	$ 0.4

XML 47 R35.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Segment Information (Details)	6 Months Ended
	Jun. 30, 2020 segment
Summary of Significant Accounting Policies
Number of operating segments	1

XML 48 R36.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Series A Convertible Preferred Stock (Details) - Series A - shares	Jun. 30, 2020	Dec. 31, 2019	Oct. 14, 2014
Preferred stock, Common Stock and Warrant Offering
Convertible preferred stock, shares authorized			1,250,000
Convertible preferred stock, shares outstanding	85,581	85,581
Stock issued as a result of conversion (in shares)	0

XML 49 R37.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Series C Preferred Stock Issuances and Beneficial Conversion Feature (Details) - $ / shares	Jul. 03, 2018	Jun. 30, 2020	Dec. 31, 2019
Warrants
Preferred stock, Common Stock and Warrant Offering
Warrants issued (in shares)	88,928
Series C
Preferred stock, Common Stock and Warrant Offering
Preferred shares issued (in shares)		1,827	1,827
Convertible preferred stock, par value	$ 1,000	$ 1,000	$ 1,000
Issuance of stock, net (in shares)	10,826
Preferred Stock, Shares Outstanding		1,827	1,827
Stock issued as a result of conversion (in shares)		0
Series C \| Preferred Stock
Preferred stock, Common Stock and Warrant Offering
Preferred shares issued (in shares)	1

XML 50 R38.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Common Stock and Warrant Offering (Details)	Apr. 25, 2017 USD ($) $ / shares shares	Apr. 04, 2016 USD ($) $ / shares shares	Oct. 13, 2015 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares	Dec. 31, 2019 USD ($) $ / shares
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants				$ 34,398	$ 5,623
Level 3 \| Warrants
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants				$ 34,398	$ 5,623
October 13 2015
Common Stock and Warrant Offering
Issuance of stock, net (in shares) \| shares			8,929
Fixed combined price (in dollars per share) \| $ / shares			$ 1,680
Proceeds from issuance of stock			$ 15,000,000
Offering costs			1,500,000
Additional proceeds if warrants exercised in full			$ 12,800,000
Price of Hepion common stock \| $ / shares				$ 2.86	$ 5.36
October 13 2015 \| Expected warrant term (years)
Common Stock and Warrant Offering
Measurement input				0.28	0.78
October 13 2015 \| Risk-free interest rate
Common Stock and Warrant Offering
Measurement input				0.24	1.66
October 13 2015 \| Expected volatility
Common Stock and Warrant Offering
Measurement input				140	72
October 13 2015 \| Warrants
Common Stock and Warrant Offering
Warrants issued (in shares) \| shares			5,357
Exercise period for warrants			5 years
Exercise price per share \| $ / shares			$ 2,380.00
Fundamental transaction period			90 days
October 13 2015 \| Level 3 \| Warrants
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants			$ 4,400,000
April 4 2016
Common Stock and Warrant Offering
Issuance of stock, net (in shares) \| shares		8,803
Fixed combined price (in dollars per share) \| $ / shares		$ 795.20
Proceeds from issuance of stock		$ 7,000,000
Offering costs		700,000
Additional proceeds if warrants exercised in full		$ 4,200,000
Price of Hepion common stock \| $ / shares				$ 2.86	$ 5.36
April 4 2016 \| Expected warrant term (years)
Common Stock and Warrant Offering
Measurement input				0.76	1.26
April 4 2016 \| Risk-free interest rate
Common Stock and Warrant Offering
Measurement input				0.24	1.66
April 4 2016 \| Expected volatility
Common Stock and Warrant Offering
Measurement input				128.00	75.00
April 4 2016 \| Warrants
Common Stock and Warrant Offering
Warrants issued (in shares) \| shares		4,401
Exercise period for warrants		5 years
Exercise price per share \| $ / shares		$ 952.00
Fundamental transaction period		90 days
April 4 2016 \| Level 3 \| Warrants
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants		$ 1,500,000
April 25 2017
Common Stock and Warrant Offering
Issuance of stock, net (in shares) \| shares	21,429
Fixed combined price (in dollars per share) \| $ / shares	$ 560.00
Proceeds from issuance of stock	$ 12,000,000
Offering costs	$ 500,000
Fundamental transaction period	90 days
Additional proceeds if warrants exercised in full	$ 7,500,000
Price of Hepion common stock \| $ / shares				$ 2.86	$ 5.36
April 25 2017 \| Expected warrant term (years)
Common Stock and Warrant Offering
Measurement input				1.81	2.31
April 25 2017 \| Risk-free interest rate
Common Stock and Warrant Offering
Measurement input				0.24	1.66
April 25 2017 \| Expected volatility
Common Stock and Warrant Offering
Measurement input				117	69
April 25 2017 \| Warrants
Common Stock and Warrant Offering
Warrants issued (in shares) \| shares	10,714
Exercise period for warrants	5 years
Exercise price per share \| $ / shares	$ 700.00
April 25 2017 \| Level 3 \| Warrants
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants	$ 4,000,000
July 3 2018
Common Stock and Warrant Offering
Price of Hepion common stock \| $ / shares				$ 2.86	$ 5.36
July 3 2018 \| Expected warrant term (years)
Common Stock and Warrant Offering
Measurement input				3.01	3.50
July 3 2018 \| Risk-free interest rate
Common Stock and Warrant Offering
Measurement input				0.24	1.66
July 3 2018 \| Expected volatility
Common Stock and Warrant Offering
Measurement input				119	65

XML 51 R39.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Components of changes (Details) - Warrants	6 Months Ended
	Jun. 30, 2020 USD ($) shares
Number of Warrants Outstanding
Balance at the beginning of the period (in shares) \| shares	107,998
Balance at end of period (in shares) \| shares	107,998
Level 3
Derivative Instrument Liability
Balance at the beginning of the period	$ 5,623
Change in fair value of warrants	28,775
Balance at end of period	$ 34,398

XML 52 R40.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Common Stock Offering (Details) - USD ($)			6 Months Ended
	Mar. 27, 2020	Feb. 12, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Controlled equity offering sales agreement
Common stock, par value			$ 0.0001		$ 0.0001
Proceeds from issuance of stock			$ 11,248,814	$ 5,844,530
Sales Agreement
Controlled equity offering sales agreement
Common stock, par value		$ 0.0001
Maximum aggregate offering price		$ 7,000,000
Issuance of stock, net (in shares)			5,262,806
Proceeds from issuance of stock	$ 4,600,000		$ 11,200,000

XML 53 R41.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details)	1 Months Ended		6 Months Ended
Fair Value Measurements (Details)	Oct. 31, 2018 USD ($) shares	Jun. 30, 2016	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)	Jun. 10, 2016 $ / shares
Fair value measurements
Contingent consideration			$ 2,510,000		$ 2,430,000
Change in fair value of contingent consideration
Change in fair value of contingent consideration			80,000	$ 50,000
Discount rate
Change in fair value of contingent consideration
Measurement Input						6.5
Share Price
Change in fair value of contingent consideration
Measurement Input \| $ / shares						19.60
Ciclofilin
Change in fair value of contingent consideration
Payment of contingent consideration milestone	$ 1,000,000
Number of shares issued \| shares	1,439
Issuance of common stock in conjunction with milestone payment	$ 55,398
Percentage of issued and outstanding	2.50%	2.50%
Level 3 \| Contingent Consideration
Change in fair value of contingent consideration
Balance at beginning of the period			2,430,000
Change in fair value recorded in earnings			80,000
Balance at end of the period			2,510,000
Recurring basis
Fair value measurements
Contingent consideration			2,510,000		2,430,000
Derivative liabilities related to warrants			34,398		5,623
Recurring basis \| Level 3
Fair value measurements
Contingent consideration			2,510,000		2,430,000
Derivative liabilities related to warrants			$ 34,398		$ 5,623

XML 54 R42.htm IDEA: XBRL DOCUMENT

Indefinite-lived Intangible Assets and Goodwill - IPR&D (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Indefinite-lived Intangible Assets and Goodwill
In-process research and development, beginning balance	$ 3,190,000
In-process research and development, ending balance	3,190,000
Impairment losses on IPR&D	$ 0	$ 0

XML 55 R43.htm IDEA: XBRL DOCUMENT

Indefinite-lived Intangible Assets and Goodwill - Goodwill (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Roll-forward of goodwill balance
Beginning balance	$ 1,870,924
Ending balance	1,870,924
Impairment on goodwill	$ 0	$ 0

XML 56 R44.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accrued Liabilities
Payroll and related costs	$ 381,519	$ 346,244
Stock-based compensation	390,488
Research and development	493,491	12,075
Legal fees		2,354
Accrued taxes	89,389	74,357
Other	1,283	58,606
Total accrued expenses	$ 1,356,170	$ 493,636

XML 57 R45.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments - Equity Incentive Plan (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jun. 03, 2013	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jul. 31, 2020	Feb. 21, 2018	Dec. 14, 2016	Dec. 02, 2014
Stock based compensation expense
Stock-based compensation expense				$ 402,857	$ 34,637
Equity Incentive Plan
Accounting for Shared-Based Payments
Vesting period (in years)	3 years
Contractual term	10 years
Authorized shares (in shares)							40,535	13,750	11,607
Current liability of awards granted		$ 400,000		$ 400,000
Available shares (in shares)		0		0
Stock based compensation expense
Stock-based compensation expense		$ 394,611	$ 17,192	$ 402,857	34,698
General and administrative \| Equity Incentive Plan
Stock based compensation expense
Stock-based compensation expense		310,718	10,377	316,628	20,742
Research and development \| Equity Incentive Plan
Stock based compensation expense
Stock-based compensation expense		$ 83,893	$ 6,815	$ 86,229	$ 13,956
Forecast \| Equity Incentive Plan
Accounting for Shared-Based Payments
Authorized shares (in shares)						2,500,000

XML 58 R46.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments - Activity (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Number of Options
Granted (in shares)		0
Stock options
Number of Options
Balance outstanding at the beginning of the period (in shares)	41,271
Granted (in shares)	1,361,500
Balance outstanding at the end of the period (in shares)	1,402,771		41,271
Vested awards and those expected to vest at the end of the period (in shares)	1,339,385
Vested and exercisable at the end of the period (in shares)	14,530
Weighted Average Exercise Price Per Share
Balance outstanding (in dollars per share)	$ 7.76		$ 194.83
Granted (in dollars per share)	1.65
Vested awards and those expected to vest at the end of the period (in dollars per share)	8.04
Vested and exercisable at the end of the period (in dollars per share)	$ 586.70
Intrinsic Value
Balance outstanding at the beginning of the period (in dollars)	$ 43,182
Granted (in dollars)	1,647,415
Balance outstanding at the end of the period (in dollars)	1,641,645		$ 43,182
Vested awards and those expected to vest at the end of the period (in dollars)	$ 1,537,890
Weighted Average Remaining Contractual Term (in years)
Balance outstanding term (in years)	9 years 8 months 19 days		8 years 5 months 1 day
Vested awards and those expected to vest at the end of the period (in years)	9 years 8 months 19 days
Vested and exercisable at the end of the period (in years)	6 years 3 months 7 days
Unrecognized compensation cost related to non-vested stock options and RSUs outstanding
Unrecognized compensation cost related to non-vested stock (in dollars)	$ 3,300,000
Weighted average remaining vesting period over which unrecognized compensation is expected to be recognized	2 years 4 months 24 days
Stock options \| Exercise price range $3.24-$2,452.80
Exercise Price Per Share
Exercise price, low end of the range (in dollars per share)	$ 3.24		$ 3.24
Exercise price, high end of the range (in dollars per share)	2,452.80		$ 2,452.80
Stock options \| Exercise price range $1.65-$2.73
Exercise Price Per Share
Exercise price, low end of the range (in dollars per share)	1.63
Exercise price, high end of the range (in dollars per share)	$ 2.73

XML 59 R47.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments - Assumptions (Details)		3 Months Ended		6 Months Ended		9 Months Ended
	Apr. 01, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2016
Weighted-average assumptions to determine fair value of stock option awards
Actual forfeiture rate (as a percent)		3.00%	10.00%	3.00%	3.00%	3.00%
Estimated future unvested option forfeitures (as a percent)	10.00%

XML 60 R48.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details) - Stock options	6 Months Ended
	Jun. 30, 2020 $ / shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock price	$ 1.65
Risk-free interest rate	0.36%
Expected volatility	126.30%
Expected term (in years)	6 years

XML 61 R49.htm IDEA: XBRL DOCUMENT

Loss per Share (Details) - USD ($)	3 Months Ended				6 Months Ended
Loss per Share (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Numerator:
Net loss	$ (4,940,080)	$ (4,226,617)	$ (1,020,898)	$ (1,983,711)	$ (9,166,697)	$ (3,004,610)
Preferred stock deemed dividend			(5,412,045)			(5,436,366)
Net loss attributable to common shareholders	$ (4,940,080)		$ (6,432,943)		$ (9,166,697)	$ (8,440,976)
Denominator:
Weighted average common shares outstanding (in shares)	8,494,518		859,827		6,420,109	556,662
Net loss per share of common stock-basic and diluted (in dollars per share)	$ (0.58)		$ (7.48)		$ (1.43)	$ (15.16)
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)					3,959,360	2,870,254
Series A
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)					3,184	3,184
Series C
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)					16,839	16,987
Stock options
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)					1,402,771	9,010
Warrants – liability classified
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)					107,998	107,997
Warrants
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)					2,428,568	2,733,076

XML 62 R50.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Contractual Obligations (Details)	Oct. 31, 2019	May 31, 2018	Dec. 31, 2017
Corporate office space
Contractual Obligations
Renewal term (in years)			5 years
Office equipment
Contractual Obligations
Term (in years)		3 years
Office and research laboratory
Contractual Obligations
Term (in years)	3 years

XML 63 R51.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Leases (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Jan. 01, 2019
Lessee, Lease, Description [Line Items]
Operating lease liability	$ 692,862
ROU assets	672,801	$ 797,913
Current lease liabilities	274,604	266,696
Non-current lease liabilities	$ 418,258	$ 540,751
Estimated incremental borrowing rate (as a percent)	6.50%
ASU 2016-02
Lessee, Lease, Description [Line Items]
Operating lease liability			$ 800,000
ROU assets			$ 800,000

XML 64 R52.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Future minimum rental payments under the Company's noncancelable operating leases (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases
Rent expense	$ 100,000	$ 100,000	$ 200,000	$ 100,000
Weighted average remaining term (in years)	2 years 7 months 17 days		2 years 7 months 17 days
Future minimum rental payments
2020	$ 141,670		$ 141,670
2021	285,201		285,201
2022	269,751		269,751
2023	53,902		53,902
Total	750,524		750,524
Present value adjustment	(57,662)		(57,662)
Lease liability at June 30, 2020	$ 692,862		$ 692,862

EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 199 308 1 false 45 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.hepion.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.hepion.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.hepion.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.hepion.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Equity Sheet http://www.hepion.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders??? Equity Statements 5 false false R6.htm 00400 - Statement - Consolidated Statements of Cash Flows Sheet http://www.hepion.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Business Overview Sheet http://www.hepion.com/role/DisclosureBusinessOverview Business Overview Notes 7 false false R8.htm 10201 - Disclosure - Basis of Presentation and Going Concern Sheet http://www.hepion.com/role/DisclosureBasisOfPresentationAndGoingConcern Basis of Presentation and Going Concern Notes 8 false false R9.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10401 - Disclosure - Recent Accounting Pronouncements Sheet http://www.hepion.com/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 10 false false R11.htm 10501 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrants Stockholders' Equity and Derivative Liability - Warrants Notes 11 false false R12.htm 10601 - Disclosure - Fair Value Measurements Sheet http://www.hepion.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 10701 - Disclosure - Indefinite-lived Intangible Assets and Goodwill Sheet http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwill Indefinite-lived Intangible Assets and Goodwill Notes 13 false false R14.htm 10801 - Disclosure - Accrued Liabilities Sheet http://www.hepion.com/role/DisclosureAccruedLiabilities Accrued Liabilities Notes 14 false false R15.htm 10901 - Disclosure - Accounting for Share-Based Payments Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPayments Accounting for Share-Based Payments Notes 15 false false R16.htm 11001 - Disclosure - Loss per Share Sheet http://www.hepion.com/role/DisclosureLossPerShare Loss per Share Notes 16 false false R17.htm 11101 - Disclosure - Commitments and Contingencies Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30503 - Disclosure - Stockholder???s Equity and Derivative Liability - Warrants (Tables) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsTables Stockholder???s Equity and Derivative Liability - Warrants (Tables) Tables 19 false false R20.htm 30603 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.hepion.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.hepion.com/role/DisclosureFairValueMeasurements 20 false false R21.htm 30703 - Disclosure - Indefinite-lived Intangible Assets and Goodwill (Tables) Sheet http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillTables Indefinite-lived Intangible Assets and Goodwill (Tables) Tables http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwill 21 false false R22.htm 30803 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.hepion.com/role/DisclosureAccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.hepion.com/role/DisclosureAccruedLiabilities 22 false false R23.htm 30903 - Disclosure - Accounting for Share-Based Payments (Tables) Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPaymentsTables Accounting for Share-Based Payments (Tables) Tables http://www.hepion.com/role/DisclosureAccountingForShareBasedPayments 23 false false R24.htm 31003 - Disclosure - Loss per Share (Tables) Sheet http://www.hepion.com/role/DisclosureLossPerShareTables Loss per Share (Tables) Tables http://www.hepion.com/role/DisclosureLossPerShare 24 false false R25.htm 31103 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.hepion.com/role/DisclosureCommitmentsAndContingencies 25 false false R26.htm 40101 - Disclosure - Business Overview (Details) Sheet http://www.hepion.com/role/DisclosureBusinessOverviewDetails Business Overview (Details) Details http://www.hepion.com/role/DisclosureBusinessOverview 26 false false R27.htm 40202 - Disclosure - Basis of Presentation and Going Concern - Going Concern (Details) Sheet http://www.hepion.com/role/DisclosureBasisOfPresentationAndGoingConcernGoingConcernDetails Basis of Presentation and Going Concern - Going Concern (Details) Details 27 false false R28.htm 40203 - Disclosure - Basis of Presentation and Going Concern - PPP Loan (Details) Sheet http://www.hepion.com/role/DisclosureBasisOfPresentationAndGoingConcernPppLoanDetails Basis of Presentation and Going Concern - PPP Loan (Details) Details 28 false false R29.htm 40301 - Disclosure - Summary of Significant Accounting Policies - Cash (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails Summary of Significant Accounting Policies - Cash (Details) Details http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 29 false false R30.htm 40302 - Disclosure - Summary of Significant Accounting Policies - Derivative financial instruments (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeFinancialInstrumentsDetails Summary of Significant Accounting Policies - Derivative financial instruments (Details) Details 30 false false R31.htm 40303 - Disclosure - Summary of Significant Accounting Policies - Property, equipment and depreciation (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndDepreciationDetails Summary of Significant Accounting Policies - Property, equipment and depreciation (Details) Details 31 false false R32.htm 40304 - Disclosure - Summary of Significant Accounting Policies - Goodwill and In-Process Research and Development (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAndInProcessResearchAndDevelopmentDetails Summary of Significant Accounting Policies - Goodwill and In-Process Research and Development (Details) Details 32 false false R33.htm 40305 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails Summary of Significant Accounting Policies - Income Taxes (Details) Details 33 false false R34.htm 40306 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails Summary of Significant Accounting Policies - Research and Development (Details) Details 34 false false R35.htm 40307 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails Summary of Significant Accounting Policies - Segment Information (Details) Details 35 false false R36.htm 40501 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Series A Convertible Preferred Stock (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsSeriesConvertiblePreferredStockDetails Stockholders' Equity and Derivative Liability - Warrants - Series A Convertible Preferred Stock (Details) Details 36 false false R37.htm 40502 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Series C Preferred Stock Issuances and Beneficial Conversion Feature (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsSeriesCPreferredStockIssuancesAndBeneficialConversionFeatureDetails Stockholders' Equity and Derivative Liability - Warrants - Series C Preferred Stock Issuances and Beneficial Conversion Feature (Details) Details 37 false false R38.htm 40503 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Common Stock and Warrant Offering (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsCommonStockAndWarrantOfferingDetails Stockholders' Equity and Derivative Liability - Warrants - Common Stock and Warrant Offering (Details) Details 38 false false R39.htm 40504 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Components of changes (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsComponentsOfChangesDetails Stockholders' Equity and Derivative Liability - Warrants - Components of changes (Details) Details 39 false false R40.htm 40505 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Common Stock Offering (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsCommonStockOfferingDetails Stockholders' Equity and Derivative Liability - Warrants - Common Stock Offering (Details) Details 40 false false R41.htm 40601 - Disclosure - Fair Value Measurements (Details) Sheet http://www.hepion.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.hepion.com/role/DisclosureFairValueMeasurementsTables 41 false false R42.htm 40701 - Disclosure - Indefinite-lived Intangible Assets and Goodwill - IPR&D (Details) Sheet http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillIprDDetails Indefinite-lived Intangible Assets and Goodwill - IPR&D (Details) Details http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillTables 42 false false R43.htm 40702 - Disclosure - Indefinite-lived Intangible Assets and Goodwill - Goodwill (Details) Sheet http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillGoodwillDetails Indefinite-lived Intangible Assets and Goodwill - Goodwill (Details) Details http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillTables 43 false false R44.htm 40801 - Disclosure - Accrued Liabilities (Details) Sheet http://www.hepion.com/role/DisclosureAccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.hepion.com/role/DisclosureAccruedLiabilitiesTables 44 false false R45.htm 40901 - Disclosure - Accounting for Share-Based Payments - Equity Incentive Plan (Details) Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPaymentsEquityIncentivePlanDetails Accounting for Share-Based Payments - Equity Incentive Plan (Details) Details 45 false false R46.htm 40902 - Disclosure - Accounting for Share-Based Payments - Activity (Details) Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPaymentsActivityDetails Accounting for Share-Based Payments - Activity (Details) Details 46 false false R47.htm 40903 - Disclosure - Accounting for Share-Based Payments - Assumptions (Details) Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPaymentsAssumptionsDetails Accounting for Share-Based Payments - Assumptions (Details) Details 47 false false R48.htm 40904 - Disclosure - Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details) Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details) Details 48 false false R49.htm 41001 - Disclosure - Loss per Share (Details) Sheet http://www.hepion.com/role/DisclosureLossPerShareDetails Loss per Share (Details) Details http://www.hepion.com/role/DisclosureLossPerShareTables 49 false false R50.htm 41101 - Disclosure - Commitments and Contingencies - Contractual Obligations (Details) Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingenciesContractualObligationsDetails Commitments and Contingencies - Contractual Obligations (Details) Details 50 false false R51.htm 41102 - Disclosure - Commitments and Contingencies - Leases (Details) Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails Commitments and Contingencies - Leases (Details) Details 51 false false R52.htm 41103 - Disclosure - Commitments and Contingencies - Future minimum rental payments under the Company's noncancelable operating leases (Details) Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderCompanySNoncancelableOperatingLeasesDetails Commitments and Contingencies - Future minimum rental payments under the Company's noncancelable operating leases (Details) Details 52 false false All Reports Book All Reports hepa-20200630.xml hepa-20200630.xsd hepa-20200630_cal.xml hepa-20200630_def.xml hepa-20200630_lab.xml hepa-20200630_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true ZIP 70 0001558370-20-010449-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-20-010449-xbrl.zip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end